(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ ~~Yes~~No ☒ ~~No ☐~~

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were ~~31,021,645~~144,857,518 shares of the Registrant’s $0.001 par value common stock outstanding as of ~~July 13, 2022.~~May 26, 2023.

As of ~~May 31, 2022~~February 28, 2023 (unaudited) and August 31, ~~2021~~2022


	May 31,			August 31,			February 28,			August 31,
	2022			2021			2023			2022
		(unaudited)						(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	12,677,446		$	8,293,162		$	609,738		$	2,178,687
Accounts receivable, net		5,166,239			1,468,429			923,556			1,017,405
Inventory, net		645,063			339,385			925,107			879,033
Other receivables, current portion		1,209,137			814,157
Other receivables								1,045,619			1,085,335
Prepaid expenses and other current assets		380,800			218,376			546,604			571,335
Total current assets		20,078,685			11,133,509			4,050,624			5,731,795

Property and equipment, net		5,931,683			6,070,291			5,449,163			5,800,648
Intangible assets, net		32,192,858			32,029,499			17,199,620			18,840,619
Right-of-use assets, net		2,222,970			2,543,396			2,250,442			2,673,934
Other receivables, net of current portion		-			692,738
Goodwill		11,366,618			9,488,848			7,539,469			7,825,844
TOTAL ASSETS	$	71,792,814		$	61,958,281		$	36,489,318		$	40,872,840

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable	$	1,621,719		$	1,449,784		$	2,040,073		$	1,800,268
Accrued expenses		1,243,792			1,129,309			1,222,832			1,116,125
Accrued interest (including amounts to related parties)		961,823			366,280			469,308			454,189
Government loans and notes payable, current portion		5,260,056			4,485,649			92,050			-
Convertible notes payable, net of discount of $0		1,875,000			-
Convertible notes payable, net of discount of $307,623								421,489			9,099,654
Contingent liability		750,860			-			62,388			534,595
Due to related parties		456,528			478,920			468,749			478,897
Debentures, related parties, current portion								911,623			-
Finance lease liability, current portion		15,982			23,184			15,938			8,890
Operating lease liability, current portion		544,690			530,797			473,628			582,088
Total current liabilities		12,730,450			8,463,923			6,178,078			14,074,706

Debentures, related parties		981,337			982,205
Notes payable, net of current portion		158,645			5,133,604
Convertible notes payable, net of discount of $5,170,205		10,252,017			-
Debentures, related parties, net of current portion								-			946,250
Government loans and notes payable, net of current portion								64,977			161,460
Finance lease liability, net of current portion		8,563			16,217			-			12,076
Operating lease liability, net of current portion		1,734,790			2,057,805			1,890,624			2,185,329
Deferred tax liability		1,499,045			1,500,372			1,392,553			1,445,448
TOTAL LIABILITIES		27,364,847			18,154,126			9,526,232			18,825,269

Commitments and contingencies		-			-			-			-

STOCKHOLDERS’ EQUITY
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2022 and August 31, 2021, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 30,659,073 and 26,610,144 shares issued and outstanding at May 31, 2022 and August 31, 2021, respectively		30,659			26,610
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 28, 2023 and August 31, 2022, respectively								-			-
Common stock; $0.001 par value; 499,000,000 shares authorized; 139,626,576 and 31,180,603 shares issued and outstanding at February 28, 2023 and August 31, 2022, respectively								139,626			31,181
Additional paid-in capital		64,620,878			54,579,396			88,320,971			66,056,824
Common stock to be issued (4,308,591 and 3,622,199 shares at May 31, 2022 and August 31, 2021)		10,096,332			9,236,607
Other comprehensive income		1,015,993			991,077
Common stock to be issued (911,392 and 4,149,633 shares at February 28, 2023 and August 31, 2022)								1,217,293			9,474,807
Other comprehensive (loss) income								(51,993	)		560,836
Accumulated deficit		(31,391,082	)		(20,969,274	)		(62,375,257	)		(53,818,489	)
Total Novo Integrated Sciences, Inc. stockholders’ equity		44,372,780			43,864,416			27,250,640			22,305,159
Noncontrolling interest		55,187			(60,261	)		(287,554	)		(257,588	)
Total stockholders’ equity		44,427,967			43,804,155			26,963,086			22,047,571
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	71,792,814		$	61,958,281		$	36,489,318		$	40,872,840

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

For the Three and ~~Nine~~Six Months Ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ (unaudited)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

For the Three and ~~Nine~~Six Months Ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ (unaudited)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

For the ~~Nine~~Six Months Ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ (unaudited)

	May 31,			May 31,			February 28,			February 28,
	Nine Months Ended						Six Months Ended
	May 31,			May 31,			February 28,			February 28,
	2022			2021			2023			2022
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(10,428,624	)	$	(2,528,965	)	$	(8,581,898	)	$	(6,684,599	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,349,434			1,118,925			1,138,797			1,467,837
Fair value of vested stock options		289,892			88,855			121,774			198,562
Common stock issued for services		676,750			660,172			-			362,750
Financing costs for debt extension								1,421,583			-
Operating lease expense		418,188			467,864			419,256			289,626
Amortization of debt discount		3,654,752			-			4,230,862			1,520,862
Foreign currency transaction losses		303,714			-			35,681			401,368
Changes in operating assets and liabilities:
Accounts receivable		(3,650,069	)		543,213			57,936			213,125
Inventory		(263,539	)		-			(78,898	)		46,135
Prepaid expenses and other current assets		(150,632	)		(143,590	)		6,143			(285,444	)
Accounts payable		117,056			(97,659	)		299,881			(422,847	)
Accrued expenses		(68,871	)		64,513			148,918			(111,479	)
Accrued interest		598,904			7,455			28,226			277,075
Operating lease liability		(406,862	)		(460,063	)		(405,082	)		(282,703	)
Net cash used in operating activities		(6,559,907	)		(279,280	)		(1,156,821	)		(3,009,732	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(190,973	)		(201,369	)		-			(192,536	)
Cash acquired from (paid for) acquisition		57,489			(10,000	)
Payment on other receivable		296,138			-
Amounts loaned for other receivables		-			(470,040	)
Net cash provided by (used in) investing activities		162,654			(681,409	)
Cash acquired with acquisition								-			29,291
Net cash used in investing activities								-			(163,245	)


CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties		(21,932	)		(177,534	)
Proceeds from (repayments to) related parties								6,138			(4,350	)
Repayments of finance leases		(14,797	)		-			(4,299	)		(10,934	)
Repayments of notes payable		(4,430,794	)		-			-			(4,415,000	)
Proceeds from the sale of common stock, net of offering costs		-			7,327,580			1,795,000			-
Proceeds from exercise of stock options		-			12,000
Proceeds from exercise of warrants								131,000			-
Repayment of convertible notes								(2,977,778	)		-
Proceeds from issuance of convertible notes, net		15,270,000			-			445,235			15,270,000
Net cash provided by financing activities		10,802,477			7,162,046
Net cash (used in) provided by financing activities								(604,704	)		10,839,716

Effect of exchange rate changes on cash and cash equivalents		(20,940	)		97,970			192,576			(15,904	)

NET INCREASE IN CASH AND CASH EQUIVALENTS		4,384,284			6,299,327
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS								(1,568,949	)		7,650,835

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		8,293,162			2,067,718			2,178,687			8,293,162

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	12,677,446		$	8,367,045		$	609,738		$	15,943,997

CASH PAID FOR:
Interest	$	1,294,912		$	33,183		$	275,990		$	1,294,912
Income taxes	$	-		$	-		$	-		$	-

SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for convertible debt settlement							$	9,086,051		$	-
Common stock to be issued for intangible assets	$	188,925		$	876,000		$	-		$	188,925
Common stock to be issued for acquisitions	$	1,244,550		$	-
Common stock issued for acquisition	$	1,704,000		$	430,837
Conversion of convertible notes payable and accrued interest to common stock	$	1,247,849		$	-
Common stock to be issued for acquisition							$	-		$	983,925
Debt discount recognized on derivative liability							$	1,390,380		$	-
Debt discount recognized on convertible note							$	297,055		$	-
Extinguishment of derivative liability due to conversion							$	1,390,380		$	-
Common stock issued with convertible notes							$	82,963		$	-
Warrants issued with convertible notes							$	86,327		$	-

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

For the ~~Nine~~Six Months Ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ (unaudited)

Novo Integrated Sciences, Inc. (“Novo Integrated” ~~or the “Company”~~) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.

The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

~~Innovation through science, combined with the integration of sophisticated, secure technology, assures Novo Integrated of continued cutting edge advancement in patient first platforms.~~

On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited ~~a wholly owned subsidiary of the Company~~ (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 16,779,741 restricted shares of Novo Integrated common stock, representing 85% of the issued and outstanding Novo Integrated common stock, calculated including all granted and issued options or warrants to acquire Novo Integrated common stock as of the Effective Date, but to exclude shares of Novo Integrated common stock that are subject to a then-current Regulation S offering that was undertaken by Novo Integrated (the “Exchange”).

On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904.

On February 1, 2021, the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. Unless otherwise noted, the share and per share information in this report have been retroactively adjusted to give effect to the 1-for-10 reverse stock ~~split.~~split.

In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. On March 17, 2020, as a result of COVID-19 pandemic having been reported throughout both Canada and the United States, certain national, provincial, state and local governmental authorities issued proclamations and/or directives aimed at minimizing the spread of COVID-19. Accordingly, on March 17, 2020, the Company closed all corporate clinics for all in-clinic non-essential services to protect the health and safety of its employees, partners, and patients. Commencing in May 2020, the Company was able to begin providing some services, and was fully operational again in June 2020. As of May 31, 2022, all corporate clinics were open and operational, with staffing shortages in some facilities due to ongoing COVID-19 residual impact, while following all mandated guidelines and protocols from Health Canada, the Ontario Ministry of Health, and the respective disciplines’ regulatory Colleges to ensure a safe treatment environment for our staff and clients, and our eldercare operations are fully operational. In addition, Acenzia Inc. (“Acenzia”), Terragenx Inc. (“Terragenx”), PRO-DIP, LLC (“PRO-DIP”), and Clinical Consultants International LLC (“CCI”), each of which is a wholly owned subsidiary of Novo Integrated, are open and fully operational, with staffing shortages due to ongoing COVID-19 residual impact, while following all local, state, provincial, and national guidelines and protocols related to minimizing the spread of the COVID-19 pandemic.

Canadian federal and provincial COVID-19 governmental proclamations and directives, including interprovincial travel restrictions, have presented unprecedented challenges to launching our Harvest Gold Farms and Kainai Cooperative joint ventures during the period ended May 31, 2022. The Company intends to commence pilot projects for each joint venture in the period ended August 31, 2022. These joint ventures relate to the development, management, and arrangement of medicinal farming projects involving industrial hemp for medicinal Cannabidiol (CBD) applications.

While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including ~~but not limited to, (i)~~ the duration of the COVID-19 outbreak, ~~and additional variants that may be identified, (ii)~~ new information which may emerge concerning the severity of the COVID-19 pandemic, and ~~(iii)~~ any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations.

For more oninformation regarding the ~~financial~~ impact of COVID-19 on the Company, see “—“Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Financial Impact of COVID-19” of this quarterly report on Form 10-Q.

The accompanying unaudited condensed consolidated financial statements were prepared ~~by the Company~~ pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations.

The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended August 31, ~~2021,~~2022, that the Company filed on ~~December 14, 2021.~~April 3, 2023. The results of operations for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 are not necessarily indicative of the results for the fiscal year ending August 31, ~~2022.~~ 2023.

The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying unaudited condensed consolidated financial statements were translated and presented in ~~United States Dollars (“$” or “USD”).~~USD.

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. The Company has incurred recurring losses from operations and has an accumulated deficit as at February 28, 2023. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the unaudited condensed consolidated financial statements are issued.

To alleviate these conditions, the Company is currently in the process of raising funds through a debt financing and a subsequent public offering in the United States. As the Company’s funding activities are ongoing, there can be no assurances that the Company will be able to secure funding on terms that are acceptable to the Company, or at all. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the unaudited condensed consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These unaudited condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction, with the CAD as the functional currency. According to ~~ASC~~ Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the condensed consolidated statement of operations and comprehensive loss. The following table details the exchange rates used for the respective periods:

	May 31, 2022		May 31, 2021		August 31, 2021		February 28, 2023		February 28, 2022		August 31, 2022

Period end: CAD to USD exchange rate	$	0.7910	$	0.8284	$	0.7917	$	0.7348	$	0.7897	$	0.7627
Average period: CAD to USD exchange rate	$	0.7897	$	0.7834	$	0.7885	$	0.7414	$	0.7911	$	0.7864

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the ~~unaudited~~ condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91% controlling interest in Terragenx Inc. (“Terragenx”), a 50.1% controlling interest in 12858461 Canada Corp (“1285 Canada”), an 80% controlling interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL, Clinical Consultants International, LLC and a 70% controlling interest in Novo Earth Therapeutics Inc. (currently inactive).

An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity.

Income or loss and each component of other comprehensive income (“OCI”) are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive loss is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.

The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss.

For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of ~~May 31, 2022,~~February 28, 2023 and August 31, ~~2021,~~2022, the allowance for uncollectible accounts receivable was $~~705,384~~936,759 and $~~1,097,628~~992,329, respectively.

Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of ~~revenue~~revenues in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021,~~2022, the Company’s allowance for slow moving or obsolete inventory was $~~1,065,777~~990,064 and $~~1,066,721~~1,027,670, respectively.

Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the period/year ended February 28, 2023 and August 31, 2022, the Company wrote off $nil and $299,672 (principal amount of $225,924 and accrued interest of $73,748), respectively, of other receivables that were not expected to be collected.

Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

The Company applies the provisions of ASC Topic 842, Leaseswhich requires lessees to recognize lease assets and lease liabilities on the balance sheet. The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate.

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including ~~right of use~~right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair ~~value is~~values are reduced for the cost of disposal. Based on its review at ~~May 31, 2022,~~February 28, 2023, the Company believes there was no impairment of its long-lived assets.

The Company’s intangible assets are being amortized over their estimated useful lives as follows:

The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, whichrequires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance ~~sheets~~sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statements of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia ~~Inc.~~ during the fiscal year ended August 31, 2021, and ~~12858461~~1285 Canada ~~Corp., Fairway Physiotherapy and Sports Injury Clinic, and Clinical Consultants International LLC~~ during the fiscal year ~~ending~~ended August 31, 2022. ~~Based on its review at May 31, 2022, the Company believes there was no impairment of its goodwill.~~ As of August 31, ~~2021,~~2022, the Company performed the required impairment reviews and determined that an impairment charge of $~~99,593~~1,357,043 related to the goodwill for ~~Executive Fitness Leaders~~Acenzia was necessary. The Company determined that the carrying value was in excess of the expected fair value of discounted cash flows based on the current market and business environments, resulting in the need for impairment. The impairment was determined based on the ~~fair value of the acquired business, which was estimated based on a~~ discounted cash flow valuation model and the projected future cash flows of the underlying business. Based on its review at February 28, 2023, the Company believes there was no additional impairment of its goodwill.

For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities.

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the condensed consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization, low risk of counterparty default and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, ~~current portion of~~ other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of government loans and notes payable, due to related parties, ~~current portion of convertible notes payable and current portion of~~debentures, operating lease liability and finance lease ~~liabilities,~~liability, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt.

As of ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021,~~2022, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair ~~value.~~value, except for cash and cash equivalents which are carried at fair value using Level 1 inputs.

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives.

The Company’s revenue recognition reflects the updated accounting policies as per the requirements of FASB Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“(“Topic 606”). As sales are and have been primarily from providing healthcare services the Company has no significant post-delivery obligations.

Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 in a manner that reasonably reflects the delivery of its products and services to customers in return for expected consideration and includes the following elements:

These five elements, as applied to the Company’s revenue category, are summarized below:

In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material.

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets.

Sales returns and allowances were insignificant for the periods ended ~~May 31, 2022~~February 28, 2023 and ~~2021.~~2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the condensed consolidated statements of operations and comprehensive loss the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. The calculations reflect the effects of the 1-for-10 reverse stock split that took place on February 1, 2021. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were ~~10,624,849~~12,466,165 and ~~1,849,600~~10,624,849 options/warrants outstanding ~~as of May 31,~~at February 28, 2023 and 2022, ~~and 2021,~~ respectively. In addition, at ~~May 31, 2022,~~February 28, 2023, there were outstanding convertible notes that could convert into ~~8,270,812~~4,835,396 shares of common stock and there were ~~4,308,591~~911,392 shares of common stock to be issued.

Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented.

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the ~~CAD.~~CAD and the functional currency of the parent company is the United States dollar. Translation ~~gains~~losses of $~~1,015,993~~617,665 and $~~991,077~~431,605 ~~at May 31, 2022~~for the period/year ended February 28, 2023 and August 31, ~~2021,~~2022, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the condensed consolidated balance ~~sheets.~~sheet.

Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets.

ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the ~~Company~~company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note ~~17.~~

~~At May 31, 2022, one customer accounted for approximately~~ 40~~% of the accounts receivable balance. This same customer also accounted for approximately~~ 70~~% and~~ 50~~% of sales during the three and nine month periods ended May 31, 2022, respectively.~~

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.

~~In June 2016, the FASB issued ASU 2016-13,~~ ~~Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments~~. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses. Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope. The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold. The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the effect of this ASU on the Company’s condensed consolidated financial statements and related disclosures.

~~In December 2019, the FASB issued ASU 2019-12,~~ ~~Simplifying the Accounting for Income Taxes~~ ~~which amends ASC 740~~ ~~Income Taxes~~ (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021. The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted. The Company is currently evaluating the effect of this ASU on the Company’s condensed consolidated financial statements and related disclosures.

~~In May, the FASB issued ASU 2021-04,~~ Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the effect of this ASU on the Company’s condensed consolidated financial statements and related disclosures.

In August 2020, the FASB issued guidance that simplifies the accounting for debt with conversion options, revises the criteria for applying the derivative scope exception for contracts in an entity’s own equity, and improves the consistency for the calculation of earnings per share. The guidance is effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2021.

In March 2020, the FASB issued guidance providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020 and can be applied through December 21, 2022, has not impacted our condensed consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2022.

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021,~~2022, the amount due to related parties was $~~456,528~~468,749 and $~~478,920~~478,897, respectively. At ~~May 31, 2022, $~~February 28, 2023, $3~~384,723~~87,350 was non-interest bearing, $~~22,763~~21,146 bears interest at 6% per annum, and $~~49,042~~60,253 bears interest at 13.75% per annum. At August 31, ~~2021,~~2022, $~~407,052~~394,405 was non-interest bearing, $~~22,783~~21,949 bears interest at 6% per annum, and $~~49,085~~62,543 bears interest at 13.75% per annum.

Accounts receivables, net at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

Inventory at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

	May 31,			August 31,			February 28,			August 31,
	2022			2021			2023			2022
Raw materials	$	1,162,067		$	1,017,566		$	695,520		$	1,259,954
Work in process		144,500			144,628			134,234			139,333
Finished Goods		404,273			243,912			1,085,417			507,416
Inventory Gross		1,710,840			1,406,106			1,915,171			1,906,703
Allowance for slow moving and obsolete inventory		(1,065,777	)		(1,066,721	)		(990,064	)		(1,027,670	)
Inventory, net	$	645,063		$	339,385		$	925,107		$	879,033

Other receivables at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

Property and equipment at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

	May 31,			August 31,			February 28,			August 31,
	2022			2021			2023			2022
Land	$	474,600		$	475,020		$	440,884		$	457,631
Building		3,559,500			3,562,650			3,306,634			3,432,232
Leasehold improvements		861,188			691,318			836,597			868,375
Clinical equipment		1,973,582			1,875,537			1,857,101			1,927,639
Computer equipment		27,116			24,679			33,315			34,579
Office equipment		49,842			46,510			44,343			45,406
Furniture and fixtures		40,983			41,019			38,071			39,518
Property and equipment gross		6,986,811			6,716,733			6,556,945			6,805,380
Accumulated depreciation		(1,055,128	)		(646,442	)		(1,107,782	)		(1,004,732	)
Total	$	5,931,683		$	6,070,291		$	5,449,163		$	5,800,648

Depreciation expense for the ~~nine~~six months ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ was $~~408,589~~ 134,123and $~~57,840~~156,067, respectively.

Certain property and equipment have been used to secure notes payable (See Note 10).

Intangible assets at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

	May 31,			August 31,			February 28,			August 31,
	2022			2021			2023			2022
Land use rights	$	21,600,000		$	21,600,000		$	11,573,321		$	11,573,321
Software license		1,144,798			1,144,798
Intellectual property		11,495,963			9,388,065			7,482,670			8,059,386
Customer relationships		786,608			787,304			2,285,915			2,320,154
Brand names		2,064,115			2,065,941			1,917,481			1,990,314
		37,091,484			34,986,108
Finite lived intangible assets, gross								23,259,387			23,943,175
Accumulated amortization		(4,898,626	)		(2,956,609	)		(6,059,767	)		(5,102,556	)
Total	$	32,192,858		$	32,029,499		$	17,199,620		$	18,840,619

Amortization expense for the ~~nine~~six months ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ was $~~1,940,845~~1,004,674 and $~~1,061,085~~1,311,770, respectively.

Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows:

Accrued expenses at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

	May 31,		August 31,		February 28,		August 31,
	2022		2021		2023		2022
Accrued liabilities	$	1,023,005	$	811,660	$	969,707	$	884,024
Accrued payroll		182,231		279,018		217,683		195,214
Unearned revenue		38,556		38,631		35,442		36,887
Accrued expenses	$	1,243,792	$	1,129,309	$	1,222,832	$	1,116,125

Notes payable at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 consisted of the following:

	May 31,			August 31,			February 28,			August 31,
	2022			2021			2023			2022
Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A).		94,920			63,336			88,177			91,526

Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75% per annum, requires monthly payments of $190 and is due 30 years from the date of issuance, and is secured by certain equipment of PRO-DIP.		40,320			40,320			40,320			40,320

Note payable dated December 3, 2019; accrues interest at 3% per annum; secured by land, building and personal property; due June 30, 2022. (On June 30, 2022, paid in full, see Note 18.)		5,252,749			5,069,858

Note payable dated December 3, 2018; accrues interest at 4.53% per annum; unsecured; annual payments of approximately $4,000; due December 31, 2028		30,712			30,739			28,530			29,614

Note payable dated June 24, 2021; accrues interest at 9% per annum; secured by real property of Acenzia; lender at its sole discretion may require monthly principal payments of $950,000 after December 24, 2021; any unpaid principal and interest due on June 24, 2022. This note was repaid during the nine months ended May 31, 2022.		-			4,415,000
Total government loans and notes payable		5,418,701			9,619,253			157,027			161,460
Less current portion		(5,260,056	)		(4,485,649	)		(92,050	)		-
Long-term portion	$	158,645		$	5,133,604		$	64,977		$	161,460

In 2020, the Government of Canada announced the Canada Emergency Wage Subsidy (“CEWS”) for Canadian employers whose businesses were affected by the COVID-19 pandemic. The CEWS provides a subsidy of up to 75% of eligible employees’ employment insurable remuneration, subject to certain criteria. Accordingly, the Company applied for the CEWS to the extent it met the requirements to receive the subsidy and during the nine months ended May 31, 2021, recorded a total of approximately $~~731,000~~ in government subsidies as a reduction to the associated wage costs recorded in cost of revenues and general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. During the nine months ended May 31, 2022, the Company did not receive any wage subsidies.

Future scheduled maturities of outstanding government loans and notes payable are as follows:

Schedule of Future Maturities Outstanding of ~~Governmental~~Government Loans and ~~Note~~Notes Payable

Twelve Months Ending May 31,
2023	$	5,260,056
Twelve Months Ending February 28,
2024		99,822	$	92,050
2025		5,343		4,768
2026		5,790		4,768
2027		6,244		4,768
2028				4,768
Thereafter		41,446		45,905
Total	$	5,418,701	$	157,027

On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $16,666,666 (the “$16.66m+ convertible notes”) with each note having a face amount of $8,333,333. The $16.66m+ convertible notes accrue interest at 55%% per annum and are due on June 14, 2023. The $16.66m+ convertible notes are secured by all assets of the Company. The $16.66m+ convertible notes are convertible at the option of the note holders to convert into shares of the Company’s common stock at $2.00 per share.

In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 5,833,334 shares of the Company’s common stock at a price of $2.00 per share. The warrants expire on December 14, 2025. The Company first determined the value of the $16.66m+ convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $7,680,156 was determined using the Black-Scholes option pricing model with the following ~~assumptions~~assumptions::

The face amount of the $16.66m+ convertible notes of $16,666,666was proportionately allocated to the $16.66m+ convertible notes and the warrants in the amount of $11,409,200and $5,257,466, respectively. The amount allocated to the warrants of $5,257,466was recorded as a discount to the convertible note and as additional paid in capital. The $16.66m+ convertible notes contained an original issue discount totaling $1,666,666and the Company also incurred $1,140,000in loan fees in connection with the $16.66m+ convertible notes. The combined total discount is $8,064,132and will be amortized over the life of the $16.66m+ convertible notes. ~~During the nine months ended May 31,~~

On November 14, 2022, the ~~Company amortized~~$16.66m+ convertible notes were amended to provide the holders with conversion rights consisting of a conversion price to the first $~~2,893,927~~ 1,000,000 of principal amount of each of the ~~debt~~notes by the lower of (i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On the same day, the Company recorded a derivative liability of $1,390,380. The fair value of the derivative liability was calculated using the Black-Scholes pricing model with the following assumptions:

The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and ~~as May 31, 2022,~~thus capped by the ~~unamortized debt discount was $5,170,205~~.otherwise undiscounted amount of the convertible notes.

During the ~~three~~six months ended ~~May 31, 2022,~~February 28, 2023, an aggregate of $~~1,244,444~~8,296,666 in principal and an aggregate of $~~3,405~~32,281 in accrued interest were converted into ~~623,929~~84,202,301 shares of common stock issued to the $16.66m+ convertible note holders. As a result of the first $1,000,000 principal conversion, the derivative liability of $1,390,380 was extinguished and recognized to additional paid-in capital. As of February 28, 2023, the derivative liability balance was $nil (August 30, 2022 - $nil).

During the six months ended February 28, 2023, the Company amortized $4,226,793 of the debt discount and as of February 28, 2023, the unamortized debt discount was $14,637.

During the six month period ended February 28, 2023, the Company made cash payments in the aggregate amount of $2,944,352 for the monthly Amortization Payment, $2,777,778 in principal and $166,574 in interest, pursuant to the terms and conditions of the $16.66m+ convertible notes. As of February 28, 2023, the aggregate principal amount owed to the $16.66m+ convertible note holders is $156,111.

In connection with the $16.66m+ convertible notes, the Company is subject to certain financial covenants which the Company was not in compliance with as of February 28, 2023. This provided the lender the right to increase the interest rate to 15% per annum and rights to first ranking over all other notes held by the Company. However, subsequent to the year end, (see Note 17) the $16.66m+ convertible notes were settled without any additional charges or penalty due to non-compliance with the $16.66m+ convertible notes financial covenants.

On November 17, 2021, Terragenx, a 9191%% owned subsidiary of the Company, issued two convertible notes payable for a total of $1,875,000 (the “$1.875m convertible notes”) with each note having a face amount of $937,500. The $1.875m convertible notes accrue interest at 11%% per annum and were due on May 17, 2022. ~~(See Note 18).~~ On June 1, 2022, the Company made an aggregated payment in full of $948,874 to Platinum Point Capital LLC, (the “Platinum Note”) including all principal and interest owed, on one of the two convertible notes payable. As previously disclosed, on June 1, 2022, the Company and Jefferson Street Capital (“Jefferson”) agreed to extend the maturity date of one of the two convertible notes (the “Jefferson Note”), to November 29, 2022 with a principal amount face value of $946,875 and interest rate that shall accrue at a rate equal to 1% per annum.

The $1.875m convertible notes are secured by all assets of the Company. The $1.875m convertible notes are convertible at the option of the note holders to convert into shares of the Company’s common stock at $3.35 per share.

In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 223,880 shares of the Company’s common stock at a price of $3.35 per share. The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $351,240 and was determined using the Black-Scholes option pricing model with the following ~~assumption~~assumptionss::

The face amount of the $1.875m convertible notes of $1,875,000 was proportionately allocated to the $1.875m convertible notes and the warrants in the amount of $1,579,176 and $295,824, respectively. The amount allocated to the warrants of $295,824 was recorded as a discount to the $1.875m convertible notes and as additional paid in capital. The $1.875m convertible notes contained an original issue discount totaling $375,000 and the Company also incurred $90,000 in loan fees in connection with these $1.875m convertible notes. The combined total discount is $760,824 and will be amortized over the life of the $1.875m convertible notes. The debt discount was fully amortized during the year ended August 31, 2022.

On December 2, 2022, the Company made a partial cash payment of $200,000 to Jefferson towards the principal owed on the Jefferson Note, leaving a balance of $746,875. On December 13, 2022, the Company, Terra and Jefferson entered into a letter agreement. Pursuant to the terms of the letter agreement, Jefferson agreed to forbear from entering an event of default under the terms of the Jefferson Note and related transaction documents until December 29, 2022.

During the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, an aggregate of $746,875 in principal and an aggregate of $10,208, in accrued interest were converted into 8,907,097 shares of common stock issued to Jefferson. Effective February 16, 2023, the Jefferson Note has been settled.

On February 23, 2023, the Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12% unsecured promissory note (the “Mast Hill Note”) with a maturity date of February 23, 2024 (the “Mast Hill Maturity Date”), in the principal sum of $573,000 (the “Mast Hill Principal Sum”). In addition, the Company issued a common stock purchase warrant for the purchase of up to 1,000,000 shares of the Company’s common stock (the “Mast Hill Warrant”) to Mast Hill pursuant to the Mast Hill SPA. Pursuant to the terms of the Mast Hill Note, the Company agreed to pay the Mast Hill Principal Sum to Mast Hill and to pay interest on the principal balance at the rate of 12% per annum. The Mast Hill Note carries an OID of $57,300. Accordingly, on the closing date, Mast Hill paid the purchase price of $515,700 in exchange for the Mast Hill Note and the Mast Hill Warrant. Mast Hill may convert the Mast Hill Note into shares of the Company’s common stock at any time at a conversion price equal to $0.175 per share, subject to adjustment as provided in the Mast Hill Note (including but not limited to certain price protection provisions in case of future dilutive offerings, subject to certain customary exempt transactions) as well as certain beneficial ownership limitations.

Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $57,300 on August 23, 2023, (ii) 57,300 on September 23, 2023, (iii) $57,300 on October 23, 2023, (iv) $100,000 on November 23, 2023, (v) $100,000 on December 23, 2023, (vi) $100,000 on January 23, 2023, and (vii) all remaining amounts owed under the Mast Hill Note on the Mast Hill Maturity Date (each of the aforementioned payments are an “Amortization Payment”). If the Company fails to make any Amortization Payment, then Mast Hill shall have the right to convert the amount of such respective Amortization Payment into shares of common stock as provided in the Mast Hill Note at the lesser of (i) the then applicable conversion price under the Mast Hill Note, or (ii) 85% of the lowest VWAP of the Company’s common stock on any trading day during the five trading days prior to the respective conversion date.

The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $750 for administrative fees. The Mast Hill Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the Mast Hill Note, Mast Hill Warrant, or Mast Hill SPA.

Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125%. Upon the occurrence of an Event of Default, additional interest will accrue from the date of the Event of Default at the rate equal to the lower of 16% per annum or the highest rate permitted by law.

The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $0.25 per share, subject to adjustment as provided in the Mast Hill Warrant. The Mast Hill Warrant also contains certain cashless exercise provisions as well as price protection provisions providing for adjustment of the number of shares of the Company’s common stock issuable upon exercise of the Mast Hill Warrant and the exercise price in case of future dilutive offerings, subject to certain customary exempt transactions. The estimated value of the warrants of $86,327 was determined using the Black-Scholes option pricing model with the following assumptions:

As additional consideration for the purchase of the Mast Hill Note and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 955,000 restricted shares of common stock (the “Commitment Shares”) to Mast Hill at closing. The Mast Hill SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the Commitment Shares as well as the shares of common stock underlying the Mast Hill Note and the Mast Hill Warrant. In addition to the beneficial ownership limitations provided in the Mast Hill Note and the Mast Hill Warrant, the sum of the number of shares of common stock that may be issued under the Mast Hill SPA (including the Commitment Shares), the Mast Hill Note, and the Mast Hill Warrant shall be limited to 19.99% of the issued and outstanding common stock on the closing date (equal to 27,720,448 shares) as further described in the Mast Hill SPA, unless shareholder approval to exceed such limitation is obtained by the Company.

The principal amount of the $573,000 convertible notes was proportionately allocated to the convertible note, common stock issued, and the warrants in the amount of $403,710, $82,963, and $86,327, respectively. The amounts allocated to the equity issuances were recorded as a discount to the convertible note and as additional paid in capital. The convertible note contained an original issue discount totaling $57,300 and the Company also incurred $70,465 in loan fees in connection with the convertible note. The combined total discount is $297,055 and will be amortized over the life of the convertible note. During the six months ended February 28, 2023, the Company amortized $~~760,824~~4,069 of the debt discount and as ~~May 31, 2022,~~February 28, 2023, the unamortized debt discount was $0292,986.

On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 (approximately $6,225,163 on September 30, 2013) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 88%% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019. On September 27, 2019, the debenture holders agreed to extend the due date to September 30, ~~2021.~~2021. On November 2, 2021, the debenture holders agreed to extend the due date to December 1, ~~202~~20233..

On January 31, 2018, the debenture holders converted 7575%% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 1,047,588 shares of the Company’s common stock. The per share price used for the conversion of each debenture was $4.11 which was determined as the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $267,768.

At ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021,~~2022, the amount of debentures outstanding was $~~981,337~~911,623 and $~~982,205~~946,250, respectively.

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate.

The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028.

The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021:~~2022:

		May 31,		August 31,			February 28,		August 31,
		2022		2021			2023		2022
	Classification on Balance Sheet					Classification on Balance Sheet
Assets
Operating lease assets	Operating lease right of use assets	$	2,222,970	$	2,543,396	Operating lease right of use assets	$	2,250,442	$	2,673,934
Total lease assets		$	2,222,970	$	2,543,396		$	2,250,442	$	2,673,934

Liabilities
Current liabilities
Operating lease liability	Current operating lease liability	$	544,690	$	530,797	Current operating lease liability	$	473,628	$	582,088
Noncurrent liabilities
Operating lease liability	Long-term operating lease liability		1,734,790		2,057,805	Long-term operating lease liability		1,890,624		2,185,329
Total lease liability		$	2,279,480	$	2,588,602		$	2,364,252	$	2,767,417

Twelve Months Ending May 31,
2023	$	707,309
Twelve Months Ending February 28,
2024		491,435		$	655,578
2025		406,221			545,682
2026		379,585			493,993
2027		378,902			509,226
2028					352,549
Thereafter		464,438			417,595
Total payments		2,827,890			2,974,623
Amount representing interest		(548,410	)		(610,371	)
Lease obligation, net		2,279,480			2,364,252
Less lease obligation, current portion		(544,690	)		(473,628	)
Lease obligation, long-term portion	$	1,734,790		$	1,890,624

During the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, the Company ~~entered~~did not enter into any new lease ~~obligation of $100,711~~.obligation.

The lease expense for the ~~nine~~six months ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ was $~~567,772~~419,256 and $~~629,029~~392,160, respectively. The cash paid under operating leases for the ~~nine~~six months ended ~~May 31,~~February 28, 2023 and 2022 ~~and 2021~~ was $~~556,445~~405,082 and $~~621,228~~381,533, respectively. At ~~May 31, 2022,~~February 28, 2023, the weighted average remaining lease terms were ~~5.55~~3.29 years and the weighted average discount rate was 88%%.

The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 55%%.

The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021~~2022 is as follows:

	May 31,			August 31,
	2022			2021			February 28,			August 31,
							2023			2022
Cost	$	209,457		$	209,457		$	209,457		$	209,457
Accumulated amortization		(178,383	)		(136,491	)		(209,457	)		(192,347	)
Net book value	$	31,074		$	72,966		$	-		$	17,110

Twelve Months Ending May 31,
2023	$	16,631
Twelve Months Ending February 28,
2024		8,092		$	16,178
Total payments		24,723			16,178
Amount representing interest		(178	)		(240	)
Lease obligation, net		24,545			15,938
Less lease obligation, current portion		(15,982	)		(15,938	)
Lease obligation, long-term portion	$	8,563		$	-

The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. At ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021,~~2022, there were 0 and 0 convertible preferred shares issued and outstanding, respectively.

The Company has authorized 499,000,000 shares of $0.001 par value common stock. On February 1, 2021, the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. At ~~May 31, 2022~~February 28, 2023 and August 31, ~~2021,~~2022, there were ~~30,659,073~~139,626,576 and ~~26,610,144~~31,180,603 common shares issued and outstanding, respectively.

During the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, the Company ~~issued:~~issued common stock as follows:

As of February 28, 2023, in connection with the acquisition of Terragenx, 1285 Canada, and Poling Taddeo Hovius Physiotherapy Professional Corp, the Company has allotted and is obligated to issue 911,392 shares of the Company’s common stock.

On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorized the issuance of up to 500,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. ~~During fiscal years 2020 and 2019, the Company did not grant any awards under~~As of February 28, 2023, the 2015 ~~Plan. The~~Plan had 498,750 shares available for award; however, the Company does not intend to issue any additional grants under the 2015 Plan.

On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 1,000,000 shares of common stock are authorized for the grant of stock options and the issuance of restricted stock, stock appreciation rights, phantom stock and performance awards to officers, directors, employees and eligible consultants to the Company or its subsidiaries. As of ~~May 31, 2022,~~February 28, 2023, the 2018 Plan had 864,900 shares available for award; however, the Company does not intend to issue any additional grants under the 2018 Plan.

On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 4,500,000 shares of common stock are authorized for issuance pursuant to the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares or other cash- or stock-based awards to officers, directors, employees and eligible consultants to the Company or its subsidiaries. Subject to adjustment as provided in the 2021 Plan, the maximum aggregate number of shares that may be issued under the 2021 Plan is eligible to be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, ~~2022.~~2023. As of ~~May 31, 2022,~~February 28, 2023, the 2021 Plan had ~~4,039,315~~3,754,665 shares available for ~~award.~~award.

					Weighted								Weighted
			Weighted		Average						Weighted		Average
			Average		Remaining		Aggregate				Average		Remaining		Aggregate
	Options		Exercise		Contractual		Intrinsic		Options		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value		Outstanding		Price		Life		Value
Outstanding, August 31, 2021		1,849,600		2.29		3.14	$	218,240
Outstanding, August 31, 2022										2,164,235		2.15		2.53	$	140,577
Granted		329,985		1.41						-
Forfeited		-								-
Exercised		-								-
Outstanding, May 31, 2022		2,179,585		2.16		2.74	$	658,069
Exercisable, May 31, 2022		1,968,096	$	2.25		2.52	$	505,797
Outstanding, February 28, 2023										2,164,235		2.17		1.98	$	-
Exercisable, February 28, 2023										2,164,235	$	2.17		1.98	$	-

The exercise price for stock options outstanding at ~~May 31, 2022:~~February 28, 2023:

For options granted during the ~~nine~~six months ended ~~May 31,~~February 28, 2022 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $1.37, and the weighted-average exercise price of such options was $1.41. No options were granted during the ~~nine~~six months ended ~~May 31,~~February 28, 2022 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

~~For options granted during the nine months ended May 31, 2021 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $3.76, and the weighted-average exercise price of such options was $3.80~~. No options were granted during the nine months ended May 31, 2021 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $~~289,892~~121,774 and $~~88,855~~154,135 during the ~~nine~~six months ended ~~May 31,~~February 28, 2023 and 2022, ~~and 2021,~~ respectively. At ~~May 31, 2022,~~February 28, 2023, the unamortized stock option expense was $~~273,991~~$nil.~~, which will be amortized into expense through February 2023.~~

The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 and ~~2021:~~2022:

	2022			2021			2023			2022

Risk-free interest rate		0.93 to 1.89	%		0.42	%		0.93 to 1.89	%		0.93 to 1.89	%
Expected life of the options		2.5 years			2.5 years			2.5 years			2.5 years
Expected volatility		281	%		268	%		281	%		281	%
Expected dividend yield		0	%		0	%		0	%		0	%

					Weighted									Weighted
			Weighted		Average							Weighted		Average
			Average		Remaining		Aggregate					Average		Remaining		Aggregate
	Warrants		Exercise		Contractual		Intrinsic		Warrants			Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value		Outstanding			Price		Life		Value
Outstanding, August 31, 2021		2,388,050		3.35		5.12	$	-
Outstanding, August 31, 2022										8,445,264			2.42		3.75	$	-
Granted		6,057,214		2.05						9,000,000			0.12
Forfeited		-								-
Exercised		-								(7,143,334	)
Outstanding, May 31, 2022		8,445,264		2.42		3.75	$	291,667
Exercisable, May 31, 2022		8,445,264	$	2.42		3.75	$	291,667
Outstanding, February 28, 2023										10,301,930			0.94		3.79	$	178,623
Exercisable, February 28, 2023										10,301,930		$	0.94		3.79	$	178,623

The exercise price for warrants outstanding at ~~May 31, 2022:~~February 28, 2023:

The Company is party to certain legal proceedings from time-to-time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our condensed consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s unaudited condensed consolidated financial position as of ~~May 31, 2022,~~February 28, 2023, results of operations, cash flows or liquidity of the Company.

On November 17, 2021, the Company and NHL, a wholly owned subsidiary of the Company, entered into that certain Share Exchange Agreement (the “Terra SEA”), dated as of November 17, 2021, by and among the Company, NHL, Terragenx Inc. (“Terra”), TMS Inc. (“TMS”), Shawn Mullins, Claude Fournier, and The Coles Optimum Health and Vitality Trust (“COHV” and collectively with TMS, Mr. Mullins and Mr. Fournier, the “Terra Shareholders”). Collectively, the Terra Shareholders owned 91~~% of the outstanding shares of Terra (the “Terra Purchased Shares”).~~

Pursuant to the terms of the Terra SEA, NHL agreed to purchase from the Terra Shareholders, and the Terra Shareholders agreed to sell to NHL, the Terra Purchased Shares on the closing date, in exchange for payment by NHL of the purchase price (the “Purchase Price”) of CAD$~~500,000~~ ~~(approximately $398,050~~) (the “Exchange”). The Purchase Price was to be paid with the issuance, by NHL to the Terra Shareholders, of certain non-voting NHL special shares exchangeable into restricted shares of the Company’s common stock (the “NHL Exchangeable Shares”). The total shares of Company common stock allotted in favor of the Terra Shareholders was calculated at a per share price of $~~3.35~~.

~~The Exchange closed on November 17, 2021.~~ ~~At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of~~ ~~910~~ ~~shares of Terra common stock, representing~~ 91~~% of Terra’s outstanding shares, and (ii) a total of~~ ~~100~~ ~~NHL Exchangeable Shares were issued to the Terra Shareholders, which NHL Exchangeable Shares are exchangeable into a total of~~ ~~118,821~~ ~~restricted shares of the Company’s common stock. As a result of the Exchange, NHL has~~ 91~~% ownership of Terra and full control of the Terra business.~~

~~In addition, the Company will issue~~ ~~500,000~~ shares of the Company’s common stock to Terry Mullins as part of an employment agreement that is considered part of the purchase price. The price of the Company’s common stock on the closing date was $~~1.59; therefore the purchase price for accounting purposes was $983,925~~. The Company acquired Terragenx to complement several of the Company’s growth initiatives including (i) to build a health science related IP portfolio, and (ii) through either acquisition, internal development, or third-party licensing distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and over-the-counter preventative and maintenance care solutions. This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, Terragenx had revenues of $~~1,521,348~~ ~~and a net loss of $115,427~~.

The business combination accounting is not yet complete and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below.

~~The purchase of Terragenx was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented.~~

On November 17, 2021, the Company entered into that certain Asset Purchase Agreement (the “Mullins APA”), dated as of November 17, 2021, by and between the Company and Terence Mullins. Pursuant to the terms of the Mullins APA, Mr. Mullins agreed to sell, and the Company agreed to purchase, all of Mr. Mullins’ right, title and interest in and to certain assets (the “Mullins IP Assets”), in exchange for a purchase price of CAD$~~2,500,000~~ ~~(approximately $1,990,250) which is to be paid as follows:~~

~~All shares issued or allotted under the terms and conditions of the Mullins APA are calculated at a value of $3.35~~ ~~per share. The price of the Company’s common stock on the closing date was $1.59; therefore the purchase price for assets acquired (Intellectual property) by the payment of item (a) above was $755,701~~ ~~and item (b) above was $188,925~~. The purchase price for item (a) above has been recorded as a contingent liability at fair value in the accompanying unaudited condensed consolidated balance sheets since the conditions for payment have not been met as of May 31, 2022. The amounts assigned to assets acquired are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date.

~~In addition,~~ ~~the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales~~ ~~reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property.~~

On October 8, 2021, the Company and NHL completed a Joint Venture Agreement (the “MiTelemed+ JV”) with EK-Tech Solutions Inc. (“EK-Tech”) to establish the joint venture company MiTelemed+ Inc., an Ontario province Canada corporation (“MiTelemed+”), to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform. At closing, EK-Tech contributed all intellectual property, source code, and core data of the iTelemed platform, valued at CAD$~~1,500,000, and NHL issued to EK-Tech, non-voting NHL Exchangeable Special Shares, free and clear of all liens and encumbrances, which are issued solely for the purpose of EK-Tech to exchange, for~~ ~~185,000~~ ~~restricted shares of Company’s common stock solely upon EK-Tech meeting terms and conditions for exchange of the NHL Exchangeable Special Shares as defined in the MiTelemed+ JV.~~ ~~The net profits and net losses of the JV will be split 50/50 between NHL and EK-Tech. As of May 31, 2022, the terms and conditions for the exchange of the NHL Exchangeable Special Shares had not been met.~~

On March 1, 2022, the Company and NHL completed a Share Exchange Agreement (the “1285 SEA”) with 12858461 Canada Corp. (“1285”), a Canada federal corporation in the business of providing clinic-based physiotherapy and related ancillary services and products, and Prashant A. Jani, a Canadian citizen and sole shareholder of 1285 (the “1285 Shareholder”), to acquire ~~50.1% ownership of 1285 for a purchase price of $68,000~~ (the “1285 Purchase Price”) paid with the issuance, by NHL to the 1285 Shareholder, of certain non-voting NHL Exchangeable Special Shares which can only be utilized for the purpose of exchange into an allotment of ~~17,000~~ restricted shares of the Company’s common stock (the “Parent 1285 SEA Shares”) at the determination of the 1285 Shareholder. The number of Parent 1285 SEA Shares was calculated by dividing the 1285 Purchase Price by $~~4.00~~ ~~per share.~~

~~This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, 1285 had revenues of $54,414~~ ~~and a net income of $15,999~~.

~~The purchase of 1285 was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented.~~

~~Asset Purchase Agreement with Poling Taddeo Hovius Physiotherapy Professional Corp., operating as Fairway Physiotherapy and Sports Injury Clinic~~

On March 1, 2022, the Company and NHL completed an Asset Purchase Agreement (the “PTHPC APA”) with Poling Taddeo Hovius Physiotherapy Professional Corp. (“PTHPC”), operating a clinic-based physiotherapy, rehabilitative, and related ancillary services and products business known as Fairway Physiotherapy and Sports Injury Clinic (“FAIR”), and Jason Taddeo, a Canadian citizen and the sole shareholder of PTHPC (the “PTHPC Shareholder”), Under the terms and conditions of the PTHPC APA, PTHPC agreed to sell, assign and transfer to NHL, free and clear of all encumbrances, other than permitted encumbrances, and NHL agreed to purchase from PTHPC all of PTHPC’s right, title and interest in and to all of its assets related to FAIR and the FAIR Business, with the exception of certain limited exclusions, and the rights, privileges, claims and properties of any kind whatsoever that are related thereto, whether owned or leased, real or personal, tangible or intangible, of every kind and description and wheresoever situated. Under the terms and conditions of the PTHPC APA, the purchase price is $~~627,000~~ (the “FAIR Purchase Price”) paid with the issuance, by NHL to the PTHPC Shareholder, of certain non-voting NHL Exchangeable Special Shares which can only be utilized for the purpose of exchange into an allotment of ~~156,750~~ restricted shares of the Company’s common stock (the “Parent PTHPC APA Shares”) at the determination of the PTHPC Shareholder. The number of Parent PTHPC APA Shares was calculated by dividing the FAIR Purchase Price by $~~4.00~~ ~~per share.~~

~~This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, PTHPC had revenues of $118,742~~ ~~and a net loss of $17,619~~.

~~The purchase of PTHPC was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented.~~

~~Membership Interest Purchase Agreement with Clinical Consultants International LLC~~

On March 17, 2022, the Company entered into a Membership Interest Purchase Agreement (the “CCI Agreement”) by and among the Company, CCI, each of the members of CCI (the “CCI Members”), and Dr. Joseph Chalil as the representative of the CCI Members.

Pursuant to the terms of the CCI Agreement, the parties agreed to enter into a business combination transaction (the “CCI Acquisition”), pursuant to which, among other things, the CCI Members will sell and assign to the Company all of their membership interests of CCI, in exchange for a total of ~~800,000~~ restricted shares of the Company’s common stock (the “Exchange Shares”). The Exchange Shares will be apportioned among the Members pro rata based on their respective membership interest ownership percentage of CCI. Following the closing of the CCI Acquisition (the “Closing”), the Company will own ~~100% of the issued and outstanding membership interests of CCI, and the CCI Members or their designees will collectively own~~ ~~800,000~~ ~~restricted shares of the Company’s common stock. The restricted shares were issued on April 7, 2022.~~

~~This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, CCI had revenues of $~~0 ~~and a net loss of $717~~.

~~The purchase of CCI was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented.~~

ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the Company for making operating decisions and assessing performance. The Company has two reportable segments: healthcare services and product sales.

The following tables summarize the Company’s segment information for the three and ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 and ~~2021:~~2022:

Healthcare services	$	-		$	-		$	-		$	-
													2023			2022			2023			2022
													Three Months Ended February 28,						Six Months Ended February 28,
	Three Months Ended May 31,						Nine Months Ended May 31,						2023			2022			2023			2022
	2022			2021			2022			2021
Sales
Healthcare services	$	2,199,889		$	2,380,974		$	6,253,089		$	6,612,374		$	2,034,154		$	1,873,577		$	4,055,368		$	4,053,200
Product sales		11,651,994			-			13,629,944			-
Product manufacturing and development														512,654			995,646			1,303,132			1,977,950
Corporate		-			-			-			-			9,701			-			617,289			-
	$	13,851,883		$	2,380,974		$	19,883,033		$	6,612,374
Sales													$	2,556,509		$	2,869,223		$	5,975,789		$	6,031,150

Gross profit
Healthcare services	$	939,542		$	1,280,458		$	2,499,608		$	2,843,354		$	770,269		$	760,424		$	1,554,300		$	1,560,066
Product sales		1,469,340			-			2,392,094			-
Product manufacturing and development														190,933			455,930			538,847			922,754
Corporate		-			-			-			-			9,701			-			617,289			-
Gross profit													$	970,903		$	1,216,354		$	2,710,436		$	2,482,820
	$	2,408,882		$	1,280,458		$	4,891,702		$	2,843,354

Loss from operations
Healthcare services													$	(219,009	)	$	(265,217	)	$	(370,700	)	$	(376,322	)
Product manufacturing and development														(589,277	)		(504,145	)		(1,144,119	)		(845,690	)
Corporate														(978,524	)		(1,351,314	)		(2,513,951	)		(2,262,323	)
Income (loss) from operations													$	(1,786,810	)	$	(2,120,676	)	$	(4,028,770	)	$	(3,484,335	)
Healthcare services	$	(239,981	)	$	255,129		$	(616,303	)	$	(99,454	)
Product sales		336,348			-			(509,342	)		-
Corporate		(1,299,113	)		(657,101	)		(3,561,436	)		(2,386,186	)
	$	(1,202,746	)	$	(401,972	)	$	(4,687,081	)	$	(2,485,640	)

Depreciation and amortization
Healthcare services	$	249,831		$	13,902		$	393,942		$	57,840		$	34,594		$	71,505		$	63,562		$	146,111
Product sales		266,166			-			852,692			-
Product manufacturing and development														207,308			334,450			516,350			586,526
Corporate		367,600			367,600			1,102,800			1,061,085			310,729			367,600			558,885			735,200
Depreciation and amortization	$	881,597		$	381,502		$	2,349,434		$	1,118,925		$	552,631		$	773,555		$	1,138,797		$	1,467,837

Capital expenditures
Healthcare services	$	-		$	200,751		$	175,418		$	201,369		$	-		$	72,139		$	-		$	176,981
Product sales		-			-			15,555			-
Product manufacturing and development														-			-			-			15,555
Corporate		-			-			-			-			-			-			-			-
Capital expenditures	$	-		$	200,751		$	190,973		$	201,369		$	-		$	72,139		$	-		$	192,536

Interest expenses
Healthcare services	$	14,532		$	21,701		$	54,686		$	68,590		$	31,201		$	20,027		$	67,504		$	40,154
Product sales		94,765			-			1,067,211			-
Product manufacturing and development														2,167			923,843			4,631			972,446
Corporate		404,101			-			686,413			-			90,499			282,312			218,974			282,312
Interest expenses	$	513,398		$	21,701		$	1,808,310		$	68,590		$	123,866		$	1,226,182		$	291,109		$	1,294,912

Net loss
Healthcare services	$	(252,122	)	$	235,867		$	(663,646	)	$	(160,492	)	$	(247,967	)	$	(282,717	)	$	(433,680	)	$	(411,524	)
Product sales		(21,153	)		-			(2,641,091	)		-
Product manufacturing and development														(597,044	)		(1,837,396	)		(1,175,620	)		(2,619,938	)
Corporate		(3,470,750	)		(651,138	)		(7,123,887	)		(2,368,473	)		(3,800,151	)		(2,748,091	)		(6,972,598	)		(3,653,137	)
Net income (loss)	$	(3,744,025	)	$	(415,271	)	$	(10,428,624	)	$	(2,528,965	)
Net loss													$	(4,645,162	)	$	(4,868,204	)	$	(8,581,898	)	$	(6,684,599	)

Healthcare services	$	-	$	-
	As of		As of
	May 31,		August 31,
	2022		2021		As of February 28, 2023		As of August 31, 2022
Total assets
Healthcare services	$	6,491,538	$	7,318,888	$	5,449,578	$	5,917,403
Product sales		24,830,711		21,427,285
Product Sales						17,813,490		19,595,269
Corporate		40,470,565		33,212,108		13,226,250		15,360,168
Total assets	$	71,792,814	$	61,958,281
					$	36,489,318	$	40,872,840

Accounts receivable
Healthcare services	$	815,833	$	953,919	$	760,117	$	585,492
Product sales		1,764,474		514,510
Product Sales						153,739		419,417
Corporate		2,585,932		-		9,700		12,496
Accounts receivable	$	5,166,239	$	1,468,429
					$	923,556	$	1,017,405
Intangible assets
Healthcare services	$	-	$	-	$	136,550	$	159,453
Product sales		7,224,895		5,958,736
Product Sales						4,224,123		5,283,333
Corporate		24,967,963		26,070,763		12,838,947		13,397,833
Intangible assets	$	32,192,858	$	32,029,499
					$	17,199,620	$	18,840,619

Goodwill
Healthcare services	$	741,209	$	557,357	$	517,866	$	537,537
Product sales		8,923,595		8,931,491
Product Sales						7,021,603		7,288,307
Corporate		1,701,814		-		-		-
Goodwill	$	11,366,618	$	9,488,848
					$	7,539,469	$	7,825,844

~~Promissory Notes Payment~~Share Issuances in Connection with Warrant Exercises

Subsequent to the period ended February 28, 2023, the Company issued an aggregate of 3,200,000 shares of common stock to certain warrant holders upon exercise of their warrants issued pursuant to the prospectus that is a part of the Company’s Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022.

Subsequent to the period ended February 28, 2023, the Company issued an aggregate of 1,075,942 shares of common stock to certain note holders upon conversion of their notes. As of May 22, 2023, (i) the principal balance owed by the Company to Hudson Bay pursuant to the senior secured $8,333,333 convertible note, dated as of December 14, 2021, as amended, issued by the Company to Hudson Bay is $0, (ii) the principal balance owed by the Company to CVI pursuant to the senior secured $8,333,333 convertible note, dated as of December 14, 2021, as amended, issued by the Company to CVI is $0; and (iii) the principal balance owed by the Company to Jefferson pursuant to the secured $746,895 convertible note, dated as of November 17, 2021, as amended, issued by the Company to Jefferson is $0.

On ~~June 1, 2022,~~March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire, pursuant to which the Company issued an 12% unsecured promissory note (the “2023 FirstFire Note”) with a maturity date of March 21, 2024, in the principal sum of $573,000 (the “Principal Sum”). In addition, the Company issued a common stock purchase warrant for the purchase of up to 1,000,000 shares of the Company’s common stock (the “2023 FirstFire Warrant”) to FirstFire pursuant to the SPA. Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay the Principal Sum to FirstFire and to pay interest on the principal balance at the rate of 12% per annum. The 2023 FirstFire Note carries an OID of $57,300. Accordingly, on the closing date, FirstFire paid the ~~balance owed on one of two Terragenx $1.875~~ ~~million convertible notes for an aggregate payment~~purchase price of $~~948,874~~515,700~~, including all principal~~ in exchange for the 2023 FirstFire Note and ~~interest owed.~~the 2023 FirstFire Warrant. FirstFire may convert the 2023 FirstFire Note into the Company’s common stock at any time at a conversion price equal to $0.175 per share, subject to adjustment as provided in the 2023 FirstFire Note (including but not limited to certain price protection provisions in case of future dilutive offerings, subject to certain customary exempt transactions) as well as certain beneficial ownership limitations.

~~Promissory Notes~~Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $57,300 on September 21, 2023, (ii) 57,300 on October 21, 2023, (iii) $57,300 on November 21, 2023, (iv) $100,000 on December 21, 2023, (v) $100,000 on January 21, 2024, (vi) $100,000 on February 21, 2024, and (vii) all remaining amounts owed under the 2023 FirstFire Note on the maturity date (each of the aforementioned payments are an “Amortization Payment”). If the Company fails to make any Amortization Payment, ~~and Extension~~then FirstFire shall have the right to convert the amount of such respective Amortization Payment into shares of common stock as provided in the 2023 FirstFire Note at the lesser of (i) the then applicable conversion price under the 2023 FirstFire Note or (ii) 85% of the lowest VWAP of the Company’s common stock on any trading day during the five trading days prior to the respective conversion date.

~~On June 1, 2022,~~The Company may prepay the ~~Company made a partial payment on principal and interest owed on one~~2023 FirstFire Note at any time prior to the date that an event of ~~two Terragenx $1.875~~ ~~million convertible notes for a payment of $192,188. On June 1, 2022,~~default (as provided in the ~~Company and the note holder agreed to extend the maturity date to~~ ~~November 29, 2022~~ ~~with a principal~~2023 FirstFire Note) occurs at an amount ~~face value of $937,500~~ ~~and interest rate that shall accrue at a rate~~ equal to ~~one percent per annum.~~the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $750 for administrative fees. The 2023 FirstFire Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2023 FirstFire Note, the 2023 FirstFire Warrant, or SPA.

~~Promissory~~Upon the occurrence of any event of default, the 2023 FirstFire Note ~~Amortization Payment~~shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125% (the “Default Amount”). Upon the occurrence of an Event of Default, additional interest will accrue from the date of the Event of Default at the rate equal to the lower of 16% per annum or the highest rate permitted by law.

~~On June 14, 2022, the Company made a cash payment~~The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $0.25 per share, subject to adjustment as provided in the ~~aggregate amount~~2023 FirstFire Warrant. The 2023 FirstFire Warrant also contains certain cashless exercise provisions as well as price protection provisions providing for adjustment of $the number of shares of common stock issuable upon exercise of the 2023 FirstFire Warrants and the exercise price in case of future dilutive offerings, subject to certain customary exempt transactions.

As additional consideration for the ~~monthly Amortization~~ ~~Payment~~purchase of the 2023 FirstFire Note and pursuant to the terms ~~and conditions~~ of the ~~$16.66m+ convertible notes~~SPA, on March 22, 2023, the Company issued 955,000. restricted shares of the Company’s common stock (the “Commitment Shares”) to FirstFire at closing. The SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the Commitment Shares as well as the shares of common stock underlying the 2023 FirstFire Note and the 2023 FirstFire Warrant. In addition to the beneficial ownership limitations provided in the 2023 FirstFire Note and the 2023 FirstFire Warrant, the sum of the number of shares of common stock that may be issued under the SPA (including the Commitment Shares), the 2023 FirstFire Note, and 2023 FirstFire Warrant shall be limited to 10,000,000 shares as further described in the SPA, unless shareholder approval to exceed such limitation is obtained by the Company.

On ~~June 29, 2022,~~April 26, 2023, the ~~Board granted Pierre Dalcourt~~Company entered into a securities purchase agreement (the “RC SPA”), dated as of April 26, 2023, with RC Consulting Group LLC in favor of SCP Tourbillion Monaco or registered assigns (the “RC Noteholder”), pursuant to which the Company issued an unsecured 15-year promissory note to the RC Noteholder (the “RC Note”) with a maturity date of ~~250,000~~April 26, 2038, in the principal sum of $70,000,000, which amount represents the $57,000,000 ~~shares~~purchase price plus a yield (non-compounding) of 1.52% (zero coupon) per annum from April 26, 2023 until the same becomes due and payable as provided in the RC Note. The RC Note may be prepaid as set forth in the RC Note and ranks pari passu with all unsecured indebtedness of the Company.

Pursuant to the terms of the RC Note, at the RC Noteholder’s option, the sale, conveyance or disposition of all or substantially all of the Company’s assets, or the consolidation, merger or other business combination of the Company with or into any other person(s) when the Company is not the survivor will either: (i) be deemed to be an Event of Default (as defined in the RC Note) pursuant to which the Company will be required to pay to the RC Noteholder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as hereinafter defined), or (ii) be treated pursuant to Section 1.6(b) of the RC Note.

The RC Note contains customary covenants for a transaction of this type. Among other things, so long as the RC Note is outstanding, the Company will not enter into any transaction or arrangement structured in accordance with, based upon, or related or pursuant to, in whole or in part, Section 3(a)(10) of the Securities Act of 1933, as amended (a “3(a)(10) Transaction”). In the event that the Company does enter into, or makes any issuance of common stock ~~pursuant~~related to a 3(a)(10) Transaction while the RC Note is outstanding, a liquidated damages charge of 25% of the outstanding principal balance of the RC Note, but not less than $1,000,000, will be assessed and will become immediately due and payable to the ~~Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan registered on~~RC Noteholder at its election in the form of a ~~Form S-8 filed by~~cash payment or added to the balance of the RC Note (under the RC Noteholder’s and the Company’s expectation that this amount will tack back to the date of issuance of the RC Note).

The RC Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the RC SPA or the RC Note.

Upon the occurrence of any Event of Default (as defined in the RC Note), the RC Note will become immediately due and payable, and the Company ~~with the Securities and Exchange Commission on February 19, 2021 (Commission File No. 333-253289 (the “2021 Plan”) as consideration for over~~ 5~~-years of service~~will pay to the ~~Board~~RC Noteholder, in full satisfaction of its obligations thereunder, an amount equal to the principal amount then outstanding plus accrued interest (including any default interest) through the date of full repayment multiplied by 125% (collectively, the “Default Amount”), as well as all costs, including, without ~~having received compensation.~~limitation, legal fees and expenses, of collection, all without demand, presentment or notice.

The RC SPA contains customary covenants, representations and warranties for a transaction of this type.

On ~~June 29,~~November 21, 2022, the ~~Board granted Michael Gaynor~~ ~~50,000~~ ~~shares of common stock pursuant to the 2021 Plan as consideration for over~~ 5~~-years of service to the Board without having~~Company received ~~compensation.~~

~~Effective June 30, 2022, Robert Oliva, Michael Gaynor and Pierre Dalcourt resigned as members of the Board of Directors. Also, effective June 30, 2022,~~ ~~(i) Sarfaraz Ali was appointed as~~ a ~~member of the Board of Directors; (ii) the size of the Board of Directors was reduced~~notification letter (the “November Notification Letter”) from seven to five members. The Board of Directors has undertaken a review of Mr. Ali’s independence and determined that Mr. Ali does not have a material relationship with the Company that could compromise his ability to exercise independent judgment in carrying out his responsibilities and that Mr. Ali is “independent” as that term is defined under the listing standards of The Nasdaq Stock Market, LLC. As a result, effective June 30, 2022, following the aforementioned Board changes, a majority of the Company’s Board of Directors is independent. As compensation for Mr. Ali’s services as a director, (“Nasdaq”) that it is ~~expected that~~not in compliance with the ~~Board will grant~~minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to ~~Mr. Ali common stock with~~maintain a ~~fair market value~~minimum bid price of $~~75,000~~1.00~~. As~~ per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of ~~June~~ 30 ~~2022,~~consecutive business days. Based on the ~~Board consists of the following 5 members:~~

Effective June 30, 2022, the Board of Directors appointed Mr. Ali to serve as a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. As of June 30, 2022, the Board committee chairs and members are as follows:

~~On June 30, 2022, the Company paid the balance owed on an Acenzia promissory note for an aggregate payment of $5,300,000, including all principal and interest owed.~~

~~On July 5, 2022, the Company issued~~ ~~50,000~~ ~~restricted shares of common stock as consideration for an Independent Contractor Agreement.~~

~~On December 14, 2021, the Company issued to certain accredited institutional investors senior secured convertible notes, which notes are convertible into shares~~closing bid price of the Company’s common stock between October 10, 2022 and November 11, 2022, the Company no longer meets the minimum bid price requirement. The November Notification Letter had no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and the common stock continued to trade on The Nasdaq Capital Market under ~~certain conditions.~~ the symbol “NVOS.”

The November Notification Letter provided that the Company had 180 calendar days, or until May 22, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

On ~~July 12, 2022,~~May 23, 2023, Nasdaq notified the Company that, although the Company has not yet regained compliance with the minimum bid price requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until November 20, 2023, to regain compliance. The determination was based in part on the Company’s written notice of its intention to cure the deficiency during the second compliance period be effecting a ~~note holder converted $25,000~~ ~~in principal and $143~~ ~~in interest of these notes resulting in~~reverse stock split, if necessary.

If the ~~issuance,~~Company does not regain compliance by November 20, 2023, then Nasdaq will notify the Company of ~~12,572~~ ~~shares of~~its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the ~~noteholder.~~delisting determination to a hearings panel.

As of the date of this Quarterly Report on 10-Q, the Company’s common stock continues to trade on Nasdaq under the symbol “NVOS.” The ~~shares were issued on July 13, 2022.~~Company intends to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), provide a safe harbor for forward-looking statements made by or on behalf of the Company. The Company and its representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission (“SEC”) and in our reports and presentations to stockholders or potential stockholders. In some cases, forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in Part I, Item 1A, “Risk Factors,” of the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, ~~2021,~~2022, as the same may be updated from time to time, including in Part II, Item 1A, “Risk Factors,” of this Quarterly Report on Form 10-Q.

Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this report are made on the basis of management’s assumptions and analyses, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances.

Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this report to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated Sciences, Inc. and its consolidated subsidiaries.

Novo Integrated Sciences, Inc. (“Novo Integrated” or the “Company”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered ~~both~~ now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

Innovation through science, combined with the integration of sophisticated, secure technology, assures usNovo Integrated of continued cutting edge advancement in patient first platforms.

Our clinicians and practitioners provide certain multidisciplinary primary health care services, and related products, beyond the medical doctor first level contact identified as primary care. Our clinicians and practitioners are not licensed medical doctors, physicians, specialist, nurses or nurse practitioners. Our clinicians and practitioners are not authorized to practice primary care medicine and they are not medically licensed to prescribe pharmaceutical based product solutions.

Our team of multidisciplinary primary health care clinicians and practitioners provide assessment, diagnosis, treatment, pain management, rehabilitation, education and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations through our 16 corporate-owned clinics, a contracted network of affiliate clinics, and eldercare related long-term care homes, retirement homes, and community-based locations in Canada.

Our specialized multidisciplinary primary health care services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy (including pre- and post-partum), acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women’s pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs including event and game coverage, and private personal training.

Additionally, we continue to expand our patient care philosophy of maintaining an on-going continuous connection with our current and future patient community, beyond the traditional confines of brick-and-mortar facilities, by extending oversight of patient diagnosis, care and monitoring, directly through various Medical Technology Platforms either in-use or under development.

The occupational therapists, physiotherapists, chiropractors, massage therapists, chiropodists and kinesiologists contracted, by NHL, to provide occupational therapy, physical therapy and fall prevention assessment services are registered with the College of Occupational Therapists of Ontario, the College of Physiotherapists of Ontario, College of Chiropractors of Ontario, College of Massage Therapists of Ontario, College of Chiropodists of Ontario, and the College of Kinesiologists of Ontario regulatory authorities.

Our strict adherence to public regulatory standards, as well as self-imposed standards of excellence and regulation, have allowed us to navigate with ease through the industry’s licensing and regulatory framework. Compliant treatment, data and administrative protocols are managed through a team of highly trained, certified health care and administrative professionals. We and our affiliates provide service to the Canadian property and casualty insurance industry, resulting in a regulated framework governed by the Financial Services Commission of Ontario.

Second Pillar – Interconnected Technology for Virtual Ecosystem of Services, Products and Digital Health Offerings

Decentralization through the integration of interconnected technology platforms has been adopted and is thriving in a variety of sectors and industries such as transportation (Uber, Lyft), real estate (Zillow, Redfin, Airbnb, VRBO), used car sales (Carvana, Vroom), stock and financial markets (Robinhood, Acorns, Webull) and so many other sectors. Yet decentralization of the non-critical primary care and wellness sector of healthcare is lagging significantly in capability and benefit for patient access and delivery of services and products. The COVID-19 pandemic has taught both patients and healthcare providers the viability, importance, and benefits of decentralized access to primary care simply through the rapid adoption of telehealth/telemedicine.

The Company’s focus on a holistic approach to patient-first health and wellness, through innovation and decentralization, includes maintaining an on-going continuous connection with our current and future patient community, beyond the traditional confines of brick-and-mortar facilities, by extending oversight of patient evaluation, diagnosis, treatment solutions, and monitoring, directly through various Medical Technology Platforms and periphery tools either in-use or under development. Through the integration and deployment of sophisticated and secure technology and periphery diagnostic tools, the Company is working to expand the reach of our non-critical primary care services and product offerings, beyond the traditional clinic locations, to geographic areas not readily providing advanced primary care service to date, including the patient’s home.

NovoConnect, the Company’s proprietary mobile application with a fully securitized tech stock, telemedicine/telehealth and remote patient monitoring fall under this Second Pillar. In October 2021, we announced the launch of MiTelemed+, Inc. (“MiTelemed”), a joint venture with EK-Tech Solutions Inc. (“EK-Tech”). MiTelemed will operate, support and expand access and functionality of iTelemed, EK-Tech’s enhanced proprietary telehealth platform. MiTelemed+, through the iTelemed platform, will allow us to offer the patient and the practitioner a sophisticated and enhanced telehealth interaction. Through the interface of sophisticated peripheral based diagnostic tools operated by skilled support workers in the patient’s remote location, we believe that the practitioner’s ability and comfort to provide a uniquely comprehensive evaluation, diagnosis, and treatment solution will be dramatically elevated.

We believe our science first approach to product offerings further emphasizes the Company’s strategic vision to innovate, evolve, and deliver over-the-counter preventative and maintenance care solutions as well as therapeutics and personalized diagnostics that enable individualized health optimization.

As the Company’s patient base grows through the expansion of its corporate owned clinics, its affiliate network, its micro-clinic facility openings, its interconnected technology platforms, and other growth initiatives, the development and distribution of high-quality wellness product solutions is integral to (i) offering effective product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population, and (ii) maintaining an on-going relationship with our patients through the customization of patient preventative and maintenance care solutions.

The Company’s product offering ecosystem is being built through strategic acquisitions and engaging in licensing agreements with partners that share our vision to provide a portfolio of products that offer an essential and differentiated solution to health and wellness globally. Our 2021 acquisitions of Acenzia, PRO-DIP and Terragenx support this Third Pillar. On March 15, 2022, PRO-DIP was issued U.S. Patent No. 11,273,965 by the U.S. Patent and Trademark Office on March 15, 2022. The ‘965 patent relates to PRO-DIP’s novel technology for manufacturing its oral supplement pouches. On April 4, 2022, NHL was granted a Natural Product Number (NPN) by Health Canada for IoNovo GO Iodine which is the Company’s forth iodine related product to recently be granted a NPN by Health Canada following IoNovo Pure Iodine, IoNovo Iodide, and IoNovo for Kids pure iodine oral spray. On March 15, 2022, PRO-DIP was issued U.S. Patent No. 11,273,965 by the U.S. Patent and Trademark Office on March 15, 2022. The ‘965 patent relates to PRO-DIP’s novel technology for manufacturing its oral supplement pouches.

We have two reportable segments: healthcare services and product sales. During the quarter ended ~~May 31, 2022,~~February 28, 2023, revenues from healthcare services and product sales ~~15.88%~~were 80% and ~~84.12%~~20%, respectively, of the Company’s total revenues for the quarter. ~~We expect the percentage of revenues generated from the product sales segment to increase at a greater rate than the revenue generated from healthcare services over the coming quarters.~~

While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations. For more information regarding the impact of COVID-19 on the Company, see “—Liquidity and Capital Resources—Financial Impact of COVID-19” of this quarterly report on Form 10-Q.

~~Share Exchange Agreement to Acquire 50.1% of 12858461 Canada Corp.~~CVI Investments, Inc. Waiver and Amendment

On March 1, 2022, the Company and NHL completed a Share Exchange Agreement (the “1285 SEA”) with 12858461 Canada Corp. (“1285”), a Canada federal corporation in the business of providing clinic-based physiotherapy and related ancillary services and products, and Prashant A. Jani, a Canadian citizen and sole shareholder of 1285 (the “1285 Shareholder”) to acquire 50.1% ownership of 1285 for a purchase price of $68,000 (the “1285 Purchase Price”) paid with the issuance, by NHL to the 1285 Shareholder, of certain non-voting NHL Exchangeable Special Shares which can only be utilized for the purpose of exchange into an allotment of 17,000 restricted shares of the Company’s common stock (the “Parent 1285 SEA Shares”) at the determination of the 1285 Shareholder. The number of Parent 1285 SEA Shares was calculated by dividing the 1285 Purchase Price by $4.00 per share.

~~Asset Purchase Agreement with Poling Taddeo Hovius Physiotherapy Professional Corp., operating as Fairway Physiotherapy and Sports Injury Clinic~~

On March 1, 2022, the Company and NHL completed an Asset Purchase Agreement (the “PTHPC APA”) with Poling Taddeo Hovius Physiotherapy Professional Corp. (“PTHPC”), operating a clinic-based physiotherapy, rehabilitative, and related ancillary services and products business known as Fairway Physiotherapy and Sports Injury Clinic (“FAIR”), and Jason Taddeo, a Canadian citizen and the sole shareholder of PTHPC (the “PTHPC Shareholder”), Under the terms and conditions of the PTHPC APA, PTHPC agreed to sell, assign and transfer to NHL, free and clear of all encumbrances, other than permitted encumbrances, and NHL agreed to purchase from PTHPC all of PTHPC’s right, title and interest in and to all of its assets related to FAIR and the FAIR Business, with the exception of certain limited exclusions, and the rights, privileges, claims and properties of any kind whatsoever that are related thereto, whether owned or leased, real or personal, tangible or intangible, of every kind and description and wheresoever situated. Under the terms and conditions of the PTHPC APA, the purchase price is $627,000 (the “FAIR Purchase Price”) paid with the issuance, by NHL to the PTHPC Shareholder, of certain non-voting NHL Exchangeable Special Shares which can only be utilized for the purpose of exchange into an allotment of 156,750 restricted shares of the Company’s common stock (the “Parent PTHPC APA Shares”) at the determination of the PTHPC Shareholder. The number of Parent PTHPC APA Shares was calculated by dividing the FAIR Purchase Price by $4.00 per share.

On March 15, 2022, PRO-DIP was issued U.S. Patent No. 11,273,965 by the U.S. Patent and Trademark Office. The ‘965 patent relates to PRO-DIP’s novel technology for manufacturing its oral supplement pouches.

~~Membership Interest Purchase Agreement with Clinical Consultants International LLC~~

~~On March 17,~~October 13, 2022, the Company entered into a ~~Membership Interest Purchase Agreement~~Waiver and Amendment (the ~~“CCI Agreement”~~“CVI Waiver and Amendment”) bywith CVI Investments, Inc. (“CVI”). Pursuant to the terms of the CVI Waiver and ~~among~~Amendment, (i) the Company ~~Clinical Consultants International LLC (“CCI”~~obtained a limited waiver from CVI with respect to certain provisions of a Warrant to Purchase Common Stock, dated as of December 14, 2021, issued by the Company to CVI (the “CVI Warrant”)~~, each~~; (ii) the Company and CVI amended certain provisions of the ~~members~~CVI Warrant; (iii) the Company obtained a limited waiver from CVI with respect to certain provisions of ~~CCI~~a Senior Secured Convertible Note, dated as of December 14, 2021, issued by the Company to CVI (the ~~“Members”~~“CVI Note”),; and ~~Dr. Joseph Chalil as~~(iv) the ~~representative~~Company and CVI amended certain provisions of the ~~Members.~~CVI Note, all as more fully described below and as set forth in the CVI Warrant and the CVI Note, as applicable.

Pursuant to the terms of the CVI Waiver and Amendment, the Company obtained a limited waiver from CVI with respect to the provisions of the CVI Warrant that would have reduced the exercise price of the CVI Warrant upon the closing of the sale of the Company’s common stock by the Company (the “Offering”) conducted as set forth in and pursuant to the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) filed by the Company on September 13, 2022, as subsequently amended and as declared effective on October 13, 2022. In addition, the Company and CVI agreed to amend the CVI Warrant to provide that the exercise price of the CVI Warrant shall be the price at which the Company’s common stock is offered for sale in the Offering.

Also pursuant to the terms of the CVI Waiver and Amendment, the Company obtained a limited waiver from CVI with respect to the provisions of the CVI Note that would have reduced the conversion price of the CVI Note upon the closing of the Offering. CVI also agreed to extend the date on which the Amortization Redemption Amount (as defined in the CVI Note) may be paid from October 14, 2022 to October 19, 2022. In addition, the Company and CVI agreed to amend the CVI Note to provide that the conversion price set forth in the CVI Note shall be the price at which the Company’s common stock is being offered for sale in the Offering.

Also on October 13, 2022, the Company entered into a Waiver and Amendment (the “Hudson Bay Waiver and Amendment”) with Hudson Bay Master Fund Ltd. (“Hudson Bay”). Pursuant to the terms of the Hudson Bay Waiver and Amendment, (i) the Company obtained a limited waiver from Hudson Bay with respect to certain provisions of a Warrant to Purchase Common Stock, dated as of December 14, 2021, issued by the Company to Hudson Bay (the “Hudson Bay Warrant”); (ii) the Company and Hudson Bay amended certain provisions of the Hudson Bay Warrant; (iii) the Company obtained a limited waiver from Hudson Bay with respect to certain provisions of a Senior Secured Convertible Note, dated as of December 14, 2021, issued by the Company to Hudson Bay (the “Hudson Bay Note”); and (iv) the Company and Hudson Bay amended certain provisions of the Hudson Bay Note, all as more fully described below and as set forth in the Hudson Bay Warrant and the Hudson Bay Note, as applicable.

Pursuant to the terms of the ~~CCI Agreement,~~Hudson Bay Waiver and Amendment, the ~~parties~~Company obtained a limited waiver from Hudson Bay with respect to the provisions of the Hudson Bay Warrant that would have reduced the exercise price of the Hudson Bay Warrant upon the closing of the Offering. In addition, the Company and Hudson Bay agreed to ~~enter into a business combination transaction (the “CCI Acquisition”),~~amend the Hudson Bay Warrant to provide that the exercise price of the Hudson Bay Warrant shall be the price at which the Company’s common stock is offered for sale in the Offering.

Also pursuant to ~~which, among other things,~~ the ~~Members will sell~~terms of the Hudson Bay Waiver and ~~assign~~Amendment, the Company obtained a limited waiver from Hudson Bay with respect to the provisions of the Hudson Bay Note that would have reduced the conversion price of the Hudson Bay Note upon the closing of the Offering. Hudson Bay also agreed to extend the date on which the Amortization Redemption Amount (as defined in the Hudson Bay Note) may be paid from October 14, 2022 to October 19, 2022. In addition, the Company ~~all~~and Hudson Bay agreed to amend the Hudson Bay Note to provide that the conversion price set forth in the Hudson Bay Note shall be the price at which the Company’s common stock is being offered for sale in the Offering.

On October 18, 2022 (the “Closing Date”), the Company sold an aggregate of ~~their membership interests~~4,000,000 units (the “Units”) for an aggregate of ~~CCI, in exchange for~~$2,000,000, at a ~~total~~purchase price $0.50 per Unit (the “Offering”), consisting of ~~800,000 restricted~~(i) 4,000,000 shares (the “Shares”) of the Company’s common stock, (ii) warrants with a three-year term to purchase 4,000,000 shares of common stock at an exercise price of $0.50 per share (the ~~“Exchange Shares”~~“Three Year Warrants”), and (iii) warrants with a five-year term to purchase 4,000,000 shares of common stock at an exercise price of $0.50 per share (the “Five Year Warrants” and together with the Three Year Warrants, the “Warrants”).

On October 13, 2022, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as exclusive placement agent thereunder (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s exclusive placement agent to solicit offers to purchase the Units, and the Common Stock and Warrants forming part of the Units, offered by the prospectus (“Prospectus”) contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the Securities and Exchange Commission on October 13, 2022 (the “Registration Statement”). The ~~Exchange Shares will be apportioned among~~Placement Agent did not purchase or sell any securities, nor was it required to arrange for the ~~Members pro rata based on their respective membership interest ownership percentage~~purchase and sale of ~~CCI. Following~~any specific number or dollar amount of securities, other than to use its “reasonable best efforts” to arrange for the sale of the securities by the Company. Accordingly, there was no minimum amount of proceeds that was a condition to closing of the ~~CCI Acquisition (the “Closing”),~~Offering.

The Offering resulted in gross proceeds to the Company of approximately $2,000,000 before deducting the Placement Agent fees and related offering expenses, and excluding proceeds to the Company, if any, that may result from the future exercise of Warrants issued in the Offering which formed part of the Units. Pursuant to the terms of the Placement Agency Agreement, the Company paid the Placement Agent a cash fee of $140,000 equal to 7.0% of the gross proceeds of the Offering as well as reimbursed the Placement Agent for its accountable expenses, resulting in net proceeds to the Company of $1,795,000.

Under the Placement Agency Agreement, the Company agreed to certain restrictions on future stock offerings, including that during the 90-day period following the Closing Date, the Company will ~~own~~not issue (or enter into any agreement to issue) any shares of common stock or common stock equivalents, subject to certain exceptions, and will not file any registration statements. In addition, during the 180-day period following the Closing Date and subject to certain exceptions, the Company is prohibited from entering into (i) a transaction that would result in the Company issuing common stock that has a variable conversion price, exercise price, or exchange rate, or such a price that would reset upon the occurrence of specified or contingent events; or (ii) a transaction in which the Company agrees to issue securities at a future determined price. Each of the Company’s officers, directors, and any holder of 10% or more of the outstanding common stock has agreed to a three-month “lock-up” with respect to their shares of common stock, including securities that are convertible into, or exchangeable or exercisable for, shares of common stock. Subject to certain exceptions, during such lock-up period these holders may not offer, sell, pledge or otherwise dispose of these securities, without the prior written consent of the Placement Agent. The Placement Agency Agreement provides that the Placement Agent’s obligations were subject to conditions contained in the Placement Agency Agreement.

Each Warrant had an exercise price of $0.50 per share and is exercisable upon issuance. As a result of the Company’s entry, on November 14, 2022, into the CVI Exchange Offer and Amendment (as hereinafter defined) and the Hudson Bay Exchange Offer and Amendment (as hereinafter defined), the exercise price of each Warrant was reduced to $0.10 per share. The Three Year Warrants and the Five Year Warrants will expire three years and five years from the date of issuance, respectively.

Each Warrant is exercisable for one share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the common stock as described in the Prospectus. Subject to certain exemptions outlined in the Three Year Warrants and Five Year Warrants, if the Company sells, enters into an agreement to sell, or grants any option to purchase, or sell, enters into an agreement to sell, or grants any right to reprice, or otherwise disposes of or issues (or announces any offer, sale, grant or any option to purchase or other disposition) any shares of common stock or Common Stock Equivalents (as defined in the Three Year Warrants and Five Year Warrants), at an effective price per share less than the exercise price of the Three Year Warrants or Five Year Warrants then in effect, the exercise price of the Three Year Warrants and Five Year Warrants will be reduced to equal the effective price per share in such dilutive issuance; provided, however, in no event will the exercise price of the Three Year Warrants and Five Year Warrants be reduced to an exercise price lower than $0.10. Additionally, on the date that is 60 calendar days immediately following the initial issuance date of the Three Year Warrants and Five Year Warrants, the exercise price will be reduced to the Reset Price (as hereinafter defined), provided that the Reset Price is less than the exercise price in effect on that date. The “Reset Price” is equal to the greater of (a) 50% of the initial exercise price or (b) 100% of the ~~issued~~lowest daily volume weighted average price per share of common stock (“VWAP”) occurring during the 60 calendar days following the issuance date of the Three Year Warrants and ~~outstanding membership interests~~Five Year Warrants.

On October 13, 2022, the (i) conversion price of ~~CCI,~~the Senior Secured Convertible Notes, and the ~~Members~~(ii) exercise price per share of common stock under the warrants to purchase common stock, issued by the Company and held by CVI Investments, Inc. and Hudson Bay Master Fund Ltd. (the “Holders”) was reduced to $0.50 per share of common stock based on the offering price of each Unit in the Offering and in accordance with waivers by the Holders, as further described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2022.

The terms of the Three Year Warrants and Five Year Warrants are governed by a Warrant Agency Agreement (the “Warrant Agency Agreement”), dated as of the Closing Date, by and between the Company and Pacific Stock Transfer Company (the “Warrant Agent”). Pursuant to the terms of the Warrant Agency Agreement, the Company agreed to indemnify the Warrant Agent in its roles as transfer agent and warrant agent, its agents and each of its stockholders, directors, officers and employees against all liabilities, including judgments, costs and reasonable counsel fees that may arise out of acts performed or ~~their designees will collectively own 800,000 restricted shares~~omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity.

On November 14, 2022, the Company entered into an exchange offer and amendment (the “CVI Exchange Offer and Amendment”) with CVI. Pursuant to the terms of the CVI Exchange Offer and Amendment, (i) the Company exchanged one share of the Company’s common ~~stock. The 800,000 restricted~~stock, for each share of common stock (the “CVI Warrant Exchange”) underlying the warrant to purchase common stock, dated as of December 14, 2021, issued by the Company to CVI (the “CVI Warrant”); and (ii) the Company and CVI amended certain provisions of the senior secured convertible note, dated as of December 14, 2021, issued by the Company to CVI (the “CVI Note”), all as more fully described below and as set forth in the CVI Warrant and the CVI Note, as applicable. On November 15, 2022 and January 5, 2023, 1,757,319 and 1,159,348 shares of common stock were issued ~~on April 7, 2022.~~under the terms and conditions of the CVI Warrant Exchange.

Pursuant to the terms of the ~~CCI Agreement,~~CVI Exchange Offer and Amendment, the Company and CVI agreed to amend the CVI Note such that (i) the Company shall pay the interest originally payable in November 2022 and December 2022 upon execution of the CVI Exchange Offer and Amendment, (ii) the Company shall pay a $50,000 extension fee to CVI ($10,000 on January 15, 2023, $10,000 on February 14, 2023, $10,000 on March 14, 2023, $10,000 on April 14, 2023, and $10,000 on May 15, 2023), (iii) the payment dates for the principal originally payable in November 2022 and December 2022 shall be extended such that 1/5 of such respective principal amount shall instead be paid on each Amortization Date (as defined in the CVI Note) during January 2023, February 2023, March 2023, April 2023, and May 2023, in addition to the Amortization Redemption Amounts (as defined in the CVI Note) (the “Amortization Redemption Amounts”) due on the aforementioned dates in 2023.

Also, pursuant to the terms of the CVI Exchange Offer and Amendment, the Company agreed to ~~(i) name, at the Closing, Dr. Chalil as the Chief Medical Officer~~hold an annual or special meeting of the Company and the President of Novomerica Healthcare Group, Inc., which is a wholly owned subsidiary of the Company, (ii) enter into an employment agreement with Dr. Chalil, and (iii) name Dr. Chalilstockholders on or prior to the ~~Company’s Board~~date that is 90 calendar days after November 14, 2022, for the purpose of ~~Directors.~~obtaining shareholder approval (“Shareholder Approval”) to amend the CVI Note as follows:

(i) the definition of Conversion Price (as defined in the CVI Note) (the “Conversion Price”) shall be amended such that, as to the first $1,000,000 of principal amount of the CVI Note converted after the date that the Shareholder Approval is obtained, the Conversion Price shall be the lower of (i) the Conversion Price in effect at such time and (ii) 82.0% of the lowest VWAP (as defined in the CVI Note) during the five trading days immediately prior to the applicable conversion date (the “Adjusted Conversion Price”), provided, however, that the portion of the first $1,000,000 of principal amount of the CVI Note that is converted pursuant to a voluntary conversion by CVI shall reduce each of the remaining Amortization Redemption Amounts proportionately on a pro rata basis;

(ii) CVI may accelerate up to four Amortization Redemption Amounts (as defined in the Notes) provided that CVI agrees to accept shares of Common Stock instead of cash for such payments at a price per share equal to the Adjusted Conversion Price as calculated on the immediately preceding Amortization Date (as defined in the CVI Note)); and

(iii) upon mutual consent by the Company and CVI, CVI may elect to utilize the Adjusted Conversion Price for the balance of the Notes.

The CVI Exchange Offer and Amendment further provides that from November 14, 2022 until 30 days following November 14, 2022, neither the Company nor any of its subsidiaries shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or any securities convertible or exchangeable into Common Stock, or (ii) enter into any agreement to amend, exchange or otherwise provide any incentive to exercise any of the warrants originally issued together with the Exchange Warrants or any other warrants of the Company that are outstanding on November 14, 2022, in each such case except with respect to certain exempt issuances.

~~The CCI Agreement may be terminated under certain customary~~Hudson Bay Master Fund Ltd. Exchange Offer and ~~limited circumstances prior~~Amendment

Also, on November 14, 2022, the Company entered into an exchange offer and amendment (the “Hudson Bay Exchange Offer and Amendment”) with Hudson Bay. Pursuant to the ~~Closing, including by either party if~~terms of the ~~conditions~~Hudson Bay Exchange Offer and Amendment, (i) the Company exchanged one share of the Company’s common stock, for each share of common stock (the “Hudson Bay Warrant Exchange”) underlying the warrant to ~~Closing~~purchase common stock, dated as of ~~an opposing party have not been satisfied or waived~~December 14, 2021, issued by the ~~applicable party~~Company to Hudson Bay (the “Hudson Bay Warrant”); and (ii) the Company and Hudson Bay amended certain provisions of the senior secured convertible note, dated as of December 14, 2021, issued by the Company to Hudson Bay (the “Hudson Bay Note”), all as more fully described below and as set forth in the Hudson Bay Warrant and the Hudson Bay Note, as applicable. On November 15, 2022, 2,916,667 shares of common stock were issued under the terms and conditions of the Hudson Bay Warrant Exchange.

Pursuant to the terms of the Hudson Bay Exchange Offer and Amendment, the Company and Hudson Bay agreed to amend the Hudson Bay Note such that (i) the Company shall pay the interest originally payable in November 2022 and December 2022 upon execution of the Hudson Bay Exchange Offer and Amendment, (ii) the Company shall pay a $50,000 extension fee to Hudson Bay ($10,000 on January 15, 2023, $10,000 on February 14, 2023, $10,000 on March 14, 2023, $10,000 on April 14, 2023, and $10,000 on May 15, 2023), (iii) the payment dates for the principal originally payable in November 2022 and December 2022 shall be extended such that 1/5 of such respective principal amount shall instead be paid on each Amortization Date (as defined in the Hudson Bay Note) during January 2023, February 2023, March 2023, April 2023, and May 2023, in addition to the Amortization Redemption Amounts (as defined in the Hudson Bay Note) (the “Amortization Redemption Amounts”) due on the aforementioned dates in 2023.

Also, pursuant to the terms of the Hudson Bay Exchange Offer and Amendment, the Company agreed to hold an annual or special meeting of stockholders on or prior to ~~April 15, 2022. The CCI Acquisition closed on April 5, 2022. See “—Closing~~the date that is 90 calendar days after November 14, 2022, for the purpose of ~~CCI Acquisition” below.~~obtaining shareholder approval (“Shareholder Approval”) to amend the Hudson Bay Note as follows:

(i) the definition of Conversion Price (as defined in the Hudson Bay Note) (the “Conversion Price”) shall be amended such that, as to the first $1,000,000 of principal amount of the Hudson Bay Note converted after the date that the Shareholder Approval is obtained, the Conversion Price shall be the lower of (i) the Conversion Price in effect at such time and (ii) 82.0% of the lowest VWAP (as defined in the Hudson Bay Note) during the five trading days immediately prior to the applicable conversion date (the “Adjusted Conversion Price”), provided, however, that the portion of the first $1,000,000 of principal amount of the Hudson Bay Note that is converted pursuant to a voluntary conversion by Hudson Bay shall reduce each of the remaining Amortization Redemption Amounts proportionately on a pro rata basis;

(ii) Hudson Bay may accelerate up to four Amortization Redemption Amounts (as defined in the Notes) provided that Hudson Bay agrees to accept shares of Common Stock instead of cash for such payments at a price per share equal to the Adjusted Conversion Price as calculated on the immediately preceding Amortization Date (as defined in the Hudson Bay Note)); and

(iii) upon mutual consent by the Company and Hudson Bay, Hudson Bay may elect to utilize the Adjusted Conversion Price for the balance of the Notes.

The Hudson Bay Exchange Offer and Amendment further provides that from November 14, 2022 until 30 days following November 14, 2022, neither the Company nor any of its subsidiaries shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or any securities convertible or exchangeable into Common Stock, or (ii) enter into any agreement to amend, exchange or otherwise provide any incentive to exercise any of the warrants originally issued together with the Exchange Warrants or any other warrants of the Company that are outstanding on November 14, 2022, in each such case except with respect to certain exempt issuances.

On ~~March 18,~~November 14, 2022, as provided in the CVI Exchange Offer and Amendment, the Company ~~issued 50,000 restricted shares~~made a cash payment, in the amount of ~~common stock~~$37,384, for the monthly interest owed on the CVI Note outstanding principal balance. On November 14, 2022, as ~~consideration~~provided in the Hudson Bay Exchange Offer and Amendment, the Company made a cash payment, in the amount of $33,056, for the monthly interest owed on the Hudson Bay Note outstanding principal balance.

On January 17, 2023, March 2, 2023, and March 14, 2023, the Company made an ~~Independent Contractor Agreement.~~interest payment on the Hudson Bay Note, to Hudson Bay, in the amount of $8,333, $625, and $208, respectively. On January 17, 2023, March 2, 2023, and March 14, 2023, pursuant to the terms of the Hudson Bay Exchange Offer and Amendment, the Company paid, to Hudson Bay, extension fees in the amount of $10,000, $10,000, and $10,000, respectively. On March 24, 2023, the Company paid to Hudson Bay an aggregate of $70,069, representing the remaining principal balance on the Hudson Bay Note ($50,000), interest on the Hudson Bay Note ($69), and extension fees ($20,000). As of March 24, 2023, the Hudson Bay Note was settled and no amounts remain due and outstanding in respect of the Hudson Bay Note.

On March ~~18, 2022,~~14, 2023, the Company ~~issued 25,000 restricted shares~~made a principal payment on the CVI Note, to CVI, in the amount of ~~common stock as consideration for~~$6,111 and an ~~Independent Contractor Agreement.~~interest payment on the CVI Note, to CVI, in the amount of $77. Also on March 14, 2023, pursuant to the terms of the CVI Exchange Offer and Amendment, the Company paid, to CVI, an extension fee in the amount of $30,000. On March 24, 2023, the Company paid to CVI an extension fee in the amount of $20,000. As of March 24, 2023, the CVI Note was settled and no amounts remain due and outstanding in respect of the CVI Note.

~~Closing of CCI Acquisition~~Nasdaq Notification—Minimum Bid Price Requirement

On ~~April 5, 2022, the CCI Acquisition closed. As a result, immediately after the Closing on April 5,~~November 21, 2022, the Company ~~owned 100%~~received a notification letter (the “November Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the ~~issued and outstanding membership interests~~minimum bid price requirement exists if the deficiency continues for a period of ~~CCI. On April 7, 2022,~~30 consecutive business days. Based on the ~~Company issued an aggregate of 800,000 restricted shares~~closing bid price of the Company’s common stock between October 10, 2022 and November 11, 2022, the Company no longer meets the minimum bid price requirement. The November Notification Letter had no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and the common stock continued to trade on The Nasdaq Capital Market under the symbol “NVOS.”

On May 23, 2023, Nasdaq notified the Company that, although the Company has not yet regained compliance with the minimum bid price requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until November 20, 2023, to regain compliance. The determination was based in part on the Company’s written notice of its intention to cure the deficiency during the second compliance period be effecting a reverse stock split, if necessary.

If the Company does not regain compliance by November 20, 2023, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to a hearings panel.

As of the date of this Quarterly Report on 10-Q, the Company’s common stock continues to trade on Nasdaq under the symbol “NVOS.”

The Company intends to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

On January 4, 2023, the Company filed with the SEC a definitive information statement on Schedule 14C (the “14C”). The 14C relates to the ~~Members~~notice to stockholders concerning the approval by written consent of stockholders holding a majority of the Company’s issued and outstanding voting securities (the “Majority Stockholders”) of the effectuation of the transactions provided for in ~~connection~~each exchange offer and amendment entered into on November 14, 2022 by the Company (the “Exchange Offers and Amendments”) with CVI and Hudson Bay, including but not limited to the following amendments to the senior secured convertible notes, dated as of December 14, 2021, issued by the Company to CVI and Hudson (the “Notes”):

(i) the definition of Conversion Price (as defined in the Notes) (the “Conversion Price”) shall be amended such that, as to the first $1,000,000 of principal amount of each of the Notes converted after the date that shareholder approval is obtained, the Conversion Price shall be the lower of (i) the Conversion Price in effect at such time and (ii) 82.0% of the lowest VWAP (as defined in Notes) during the five trading days immediately prior to the applicable conversion date (the “Adjusted Conversion Price”), provided, however, that the portion of the first $1,000,000 of principal amount of each of the Notes that is converted pursuant to a voluntary conversion by the holders of each of the Notes shall reduce each of the remaining Amortization Redemption Amounts proportionately on a pro rata basis;

(ii) Each of the holders of the Notes may accelerate up to four Amortization Redemption Amounts (as defined in the Notes) provided that such holder agrees to accept shares of Common Stock instead of cash for such payments at a price per share equal to the Adjusted Conversion Price as calculated on the immediately preceding Amortization Date (as defined in the Notes)); and

(iii) upon mutual consent by the Company and each of the holders of the Notes, such holder may elect to utilize the Adjusted Conversion Price for the balance of the Notes.

Accordingly, the Majority Stockholders approved, by written consent, the issuance of the total number of shares of Company common stock of the Company necessary to effectuate the Exchange Offers and Amendments, which is currently an indeterminate number due to the methodology of the conversion pricing as described herein and in the Exchange Offers and Amendments.

Stockholder approval of the Exchange Offers and Amendments was required by Rule 5635(d) of The Nasdaq Stock Market, which requires stockholder approval prior to a 20% issuance of securities at a price that is less than the Minimum Price (as defined in the information statement) in a transaction other than a public offering. A 20% issuance is a transaction, other than a public offering, involving the sale, issuance or potential issuance by the company of common stock (or securities convertible into or exercisable for common stock), which alone or together with sales by officers, directors or substantial stockholders of the company, equals 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance.

Such approval and consent by the Majority Stockholders constitute the approval and consent of a majority of the total number of shares of the Company’s outstanding voting stock and is sufficient under the Nevada Revised Statutes, the Company’s Amended and Restated Articles of Incorporation, as amended, and the Company’s Bylaws to approve the Exchange Offers and Amendments. Accordingly, the actions will not be submitted to the other stockholders of the Company for a vote, and the information statement has been furnished to such other stockholders to provide them with certain information concerning the actions in accordance with the ~~CCI Acquisition~~requirements of the Exchange Act, and the regulations promulgated under the Exchange Act, including Regulation 14C.

As of May 18, 2023, (i) the principal balance owed by the Company to Hudson Bay pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to Hudson Bay is $0, and (ii) the principal balance owed by the Company to CVI pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to CVI is $0. See “—Share Issuances in Connection with Note Conversions.”

As previously disclosed, on June 1, 2022, the Company and Jefferson agreed to extend the maturity date of the Jefferson Note to November 29, 2022 with a principal amount face value of $946,875 and interest rate that shall accrue at a rate equal to 1% per annum. On December 2, 2022, the Company made a partial payment of $200,000 towards the principal owed on the Jefferson Note, leaving a balance of $746,875. On December 13, 2022, the Company, Terra and Jefferson entered into a letter agreement. Pursuant to the terms of the ~~CCI Agreement.~~letter agreement, Jefferson agreed to forbear from entering an event of default under the terms of the Jefferson Note and related transaction documents until December 29, 2022. In addition, the parties agreed to release the Collateral Shares to Jefferson. Effective February 16, 2023, the Jefferson Note has been settled.

On December 15, 2022, the Company received a notification letter (the “December Notification Letter”) from Nasdaq that it was not in compliance with Nasdaq’s continued listing rules due to its failure to timely file its Annual Report on Form 10-K for the fiscal year ended August 31, 2022 (the “2022 10-K”). On January 25, 2023, the Company received a notification letter (the “January Notification Letter”) from Nasdaq advising the Company that it was not in compliance with Nasdaq’s continued listing requirements as a result of its failure to timely file the 2022 10-K and its Quarterly Report on Form 10-Q for the fiscal quarter ended February 28, 2023 (the “Form 10-Q”). On February 13, 2023, the Company submitted a plan to regain compliance with Nasdaq’s continued listing rules with respect to the 2022 10-K and the Form 10-Q. If Nasdaq accepted the Company’s plan, then Nasdaq could grant an exception of up to 180 calendar days from the due date of the 2022 10-K to regain compliance. On February 17, 2023 and March 22, 2023, based on Nasdaq’s further review, Nasdaq granted an exception to enable the Company to regain compliance with Nasdaq’s continued listing rules. The terms of the exception are as follows: on or before May 29, 2023, the Company must file the 2022 10-K, the Form 10-Q, and any other filings required by Nasdaq Listing Rule 5250(c)(1). The Company filed the 2022 10-K on April 3, 2023. The Company filed its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022 on May 24, 2023.

~~Appointment of Dr. Chalil as the Company’s Chief Medical Officer and President of Novomerica Healthcare Group, Inc.~~SwagCheck Agreement

~~In connection with the closing of the CCI Acquisition and pursuant to the terms of the CCI Agreement, on April 5,~~On December 23, 2022, the Company, ~~named Dr. Chalil as~~SwagCheck Inc. (“SWAG”), and all SWAG shareholders (collectively, the ~~Company’s Chief Medical Officer, and the President of Novomerica Healthcare Group, Inc., a wholly owned subsidiary of the Company formed for expansion of~~“SWAG Shareholders”) entered into that certain ~~medically related business in the U.S. (“NHG”~~Share Purchase Agreement (the “SWAG Agreement”). Pursuant to the terms of the ~~CCI~~SWAG Agreement, the Company ~~expects~~agreed to ~~appoint Dr. Chalil as a member~~purchase, and the SWAG Shareholders agreed to sell to the Company, 100% of the ~~Company’s Board~~outstanding shares of ~~Directors~~SWAG in exchange for $1.00 (the “SWAG Purchase”). SWAG holds a specific right of purchase of a precious gem collection (the “Gems”) as provided for in an agreement between SWAG and a Court-appointed Successor Receiver for the ~~near future.~~United States District Court for the Central District of California (the “Receiver”).

~~Chalil Employment Agreement~~The parties have made customary representations, warranties and covenants in the SWAG Agreement. In addition to certain customary closing conditions, the obligations of SWAG and the SWAG Shareholders to consummate the closing of the SWAG Purchase are subject to the satisfaction (or waiver by any of SWAG or the SWAG Shareholders), at or before the closing date, of certain conditions, including that (i) the Company will have received a financing commitment of at least $90 million by December 27, 2022, with a closing date no later than December 30, 2022, (ii) $60 million will be distributed directly to a Receiver for the purchase of the Gems by SWAG, and (iii) $30 million is a Mark-up to be distributed for the benefit of the outgoing SWAG Shareholders.

In ~~connection with Dr. Chalil’s appointment as~~addition to certain customary closing conditions in the ~~Company’s Chief Medical Officer~~SWAG Agreement, the obligations of SWAG and ~~NHG’s President,~~the SWAG Shareholders to consummate the closing of the SWAG Purchase were subject to the satisfaction (or waiver by any of SWAG or the SWAG Shareholders), at or before the closing date, of certain conditions, including that (i) the Company will have provided SWAG with a binding letter of intent (a “LOI”) by a competent financing party for financing in the amount of at least $90 million by December 27, 2022 with a closing date no later than December 30, 2022, (ii) $60 million will be distributed directly to the Receiver for the purchase of the Gems by SWAG, and (iii) $30 million is a mark-up to be distributed for the benefit of the outgoing SWAG Shareholders.

On December 30, 2022, the Company, SWAG and the SWAG Shareholders entered into ~~an executive agreement~~Amendment No. 1 to the SWAG Agreement (the ~~“Chalil Agreement”~~“SWAG Amendment”) ~~with Dr. Chalil on April 5, 2022.~~. Pursuant to the terms of the ~~Chalil Agreement,~~SWAG Amendment, the ~~Company~~parties agreed to pay Dr. Chalil an annual base salary of $400,000. In addition, the Company agreed to pay Dr. Chalil an amount equal to 10% of the net income of CCI in excess of $450,000 for each calendar year during the term of the Chalil Agreement (the “Revenue Share Payment”).

~~Dr. Chalil will also receive bonuses based on increases in the Company’s market cap valuation (“MCV”) from the date of the Chalil Agreement, with the following milestone bonus parameters:~~as follows:

~~The Company may also issue to Dr. Chalil equity awards as determined by the Board of Directors.~~

The term of the Chalil Agreement ends on the earlier of (i) April 5, 2025, and (ii) the time of the termination of Dr. Chalil’s employment pursuant to the terms of the Chalil Agreement. The term of the Chalil Agreement will be automatically extended for one or more additional terms of one year each unless either party provided notice to the other party of their desire to not renew at least 30 days prior to expiration of the then-current term.

The Company may terminate the Chalil Agreement at any time for Cause (as defined in the Chalil Agreement) or without Cause, and Dr. Chalil may terminate the Chalil Agreement at any time with or without Good Reason (as defined in the Chalil Agreement. If the Company terminates the Chalil Agreement without Cause or Dr. Chalil terminates the Chalil Agreement with Good Reason, (i) the Company will pay to Dr. Chalil any base salary, bonuses, and benefits then owed or accrued, and any unreimbursed expenses incurred by Dr. Chalil in each case through the termination date; (ii) the Company will pay to Dr. Chalil, in one lump sum, an amount equal to the greater of (1) the base salary that would have been paid to Dr. Chalil for the remainder of the then-current term, and (2) the total base salary that would have been paid to Dr. Chalil for a one year period based on the base salary as of the date of termination, and the Revenue Share Payment for the calendar year in which such termination occurs; and (iii) any equity grant already made to Dr. Chalil will, to the extent not already vested, be deemed automatically vested.

On April 28, 2022, the SEC declared effective the Company’s shelf registration statement on Form S-3 (File No. 333-264360) (the “Form S-3”) originally filed on April 18, 2022. The Form S-3 is a shelf registration statement relating to the sale of 223,880 shares of our common stock issuable to the selling stockholders upon exercise of certain warrants, currently held by the respective selling stockholders, with an exercise price of $3.35 which expire on November 17, 2024.

~~On May 2, 2022, the Company issued 50,000 restricted shares of common stock as consideration for a Consulting Agreement, dated April 20, 2022.~~

~~On May 11, 2022, the Company issued 225,000 restricted shares of common stock as consideration for a Share Exchange Agreement, dated May 28, 2021 and closed on June 24, 2021.~~

During the three month period ended May 31, 2022, the Company issued 623,929 shares of common stock as consideration for payment of an aggregate principal amount of $1,244,444 and an aggregate interest amount of $3,405 on the $16.66m+ convertible notes. The shares were issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254278), which was declared effective by the SEC on March 22, 2021.

~~On June 1, 2022, the Company paid the balance owed on one of two Terragenx $1.875 million convertible notes for an aggregate payment of $948,874, including all principal and interest owed.~~

Although the SWAG Agreement has not yet closed, the parties continue to work together with the intention of closing the transaction. Following the closing of SWAG Purchase, SWAG will be a wholly owned subsidiary of the Company and ~~Extension~~will own title to the Gems, which the Company intends to either collateralize or sell to raise capital.

On ~~June 1, 2022,~~January 25, 2023, the Company ~~made a partial payment~~issued 3,202,019 shares of common stock in exchange for certain non-voting special shares of NHL, previously issued in connection with NHL’s acquisition of Acenzia that closed on ~~principal and interest owed on one of two Terragenx $1.875 million convertible notes for a payment of $192,188. On~~ June 1, 2022, the Company and the note holder agreed to extend the maturity date to November 29, 2022 with a principal amount face value of $937,500 and interest rate that shall accrue at a rate equal to one percent per annum.

~~On June 14, 2022, the Company made a cash payment in the aggregate amount of $1,391,589 for the monthly Amortization Payment pursuant~~24, 2021. Specific to the ~~terms and conditions~~Company’s acquisition of Acenzia in June 2021, no additional NHL Exchangeable shares remain for exchange to the ~~$16.66m+ convertible notes.~~Company’s common stock.

On June 29, 2022, the Board granted Pierre Dalcourt 250,000 shares of common stock pursuant to the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan registered on a Form S-8 filed by the Company with theMast Hill Securities ~~and Exchange Commission on February 19, 2021 (Commission File No. 333-253289 (the “2021 Plan”) as consideration for over 5-years of service to the Board without having received compensation.~~Purchase Agreement & Note

On ~~June 29, 2022,~~February 23, 2023, the ~~Board granted Michael Gaynor 50,000~~Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12% unsecured promissory note (the “Mast Hill Note”) with a maturity date of February 23, 2024 (the “Mast Hill Maturity Date”), in the principal sum of $573,000 (the “Mast Hill Principal Sum”). In addition, the Company issued a common stock purchase warrant for the purchase of up to 1,000,000 shares of the Company’s common stock (the “Mast Hill Warrant”) to Mast Hill pursuant to the Mast Hill SPA. Pursuant to the terms of the Mast Hill Note, the Company agreed to pay the Mast Hill Principal Sum to Mast Hill and to pay interest on the principal balance at the rate of 12% per annum. The Mast Hill Note carries an OID of $57,300. Accordingly, on the closing date, Mast Hill paid the purchase price of $515,700 in exchange for the Mast Hill Note and the Mast Hill Warrant. Mast Hill may convert the Mast Hill Note into shares of the Company’s common stock at any time at a conversion price equal to $0.175 per share, subject to adjustment as provided in the Mast Hill Note (including but not limited to certain price protection provisions in case of future dilutive offerings, subject to certain customary exempt transactions) as well as certain beneficial ownership limitations.

Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $57,300 on August 23, 2023, (ii) 57,300 on September 23, 2023, (iii) $57,300 on October 23, 2023, (iv) $100,000 on November 23, 2023, (v) $100,000 on December 23, 2023, (vi) $100,000 on January 23, 2023, and (vii) all remaining amounts owed under the Mast Hill Note on the Mast Hill Maturity Date (each of the aforementioned payments are an “Amortization Payment”). If the Company fails to make any Amortization Payment, then Mast Hill shall have the right to convert the amount of such respective Amortization Payment into shares of common stock ~~pursuant~~as provided in the Mast Hill Note at the lesser of (i) the then applicable conversion price under the Mast Hill Note, or (ii) 85% of the lowest VWAP of the Company’s common stock on any trading day during the five trading days prior to the ~~2021 Plan as consideration for over 5-years of service to the Board without having received compensation.~~respective conversion date.

~~BOD~~The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and ~~Committee Changes~~unpaid interest (no prepayment premium) plus $750 for administrative fees. The Mast Hill Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the Mast Hill Note, Mast Hill Warrant, or Mast Hill SPA.

~~Effective June 30, 2022, Robert Oliva, Michael Gaynor~~Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and ~~Pierre Dalcourt resigned as members~~payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125%. Upon the occurrence of an Event of Default, additional interest will accrue from the date of the ~~Board~~Event of ~~Directors. Also, effective June 30, 2022, (i) Sarfaraz Ali was appointed as a member~~Default at the rate equal to the lower of 16% per annum or the Board of Directors; (ii) the size of the Board of Directors was reduced from seven to five members. The Board of Directors has undertaken a review of Mr. Ali’s independence and determined that Mr. Ali does not have a material relationship with the Company that could compromise his ability to exercise independent judgment in carrying out his responsibilities and that Mr. Ali is “independent” as that term is defined under the listing standards of The Nasdaq Stock Market LLC. As a result, effective June 30, 2022, following the aforementioned Board changes, a majority of the Company’s Board of Directors is independent. As compensation for Mr. Ali’s services as a director, it is expected that the Board will grant to Mr. Ali common stock with a fair market value of $75,000. As of June 30, 2022, the Board consists of the following 5 members:highest rate permitted by law.

~~Sarfaraz Ali~~The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $0.25 per share, subject to adjustment as provided in the Mast Hill Warrant. The Mast Hill Warrant also contains certain cashless exercise provisions as well as price protection provisions providing for adjustment of the number of shares of the Company’s common stock issuable upon exercise of the Mast Hill Warrant and the exercise price in case of future dilutive offerings, subject to certain customary exempt transactions.

~~Promissory~~As additional consideration for the purchase of the Mast Hill Note ~~Payment~~and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 955,000 restricted shares of common stock (the “Commitment Shares”) to Mast Hill at closing. The Mast Hill SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the Commitment Shares as well as the shares of common stock underlying the Mast Hill Note and the Mast Hill Warrant. In addition to the beneficial ownership limitations provided in the Mast Hill Note and the Mast Hill Warrant, the sum of the number of shares of common stock that may be issued under the Mast Hill SPA (including the Commitment Shares), the Mast Hill Note, and the Mast Hill Warrant shall be limited to 19.99% of the issued and outstanding common stock on the closing date (equal to 27,720,448 shares) as further described in the Mast Hill SPA, unless shareholder approval to exceed such limitation is obtained by the Company.

On March 23, 2023, the Company made a monthly interest-only payment to Mast Hill in the amount of $5,086. On April 24, 2023, the Company made a monthly interest-only payment to Mast Hill in the amount of $5,840.

On ~~June 30, 2022,~~March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire, pursuant to which the Company issued an 12% unsecured promissory note (the “2023 FirstFire Note”) with a maturity date of March 21, 2024, in the principal sum of $573,000 (the “Principal Sum”). In addition, the Company issued a common stock purchase warrant for the purchase of up to 1,000,000 shares of the Company’s common stock (the “2023 FirstFire Warrant”) to FirstFire pursuant to the SPA. Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay the Principal Sum to FirstFire and to pay interest on the principal balance at the rate of 12% per annum. The 2023 FirstFire Note carries an OID of $57,300. Accordingly, on the closing date, FirstFire paid the ~~balance~~purchase price of $515,700 in exchange for the 2023 FirstFire Note and the 2023 FirstFire Warrant. FirstFire may convert the 2023 FirstFire Note into the Company’s common stock at any time at a conversion price equal to $0.175 per share, subject to adjustment as provided in the 2023 FirstFire Note (including but not limited to certain price protection provisions in case of future dilutive offerings, subject to certain customary exempt transactions) as well as certain beneficial ownership limitations.

Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $57,300 on September 21, 2023, (ii) 57,300 on October 21, 2023, (iii) $57,300 on November 21, 2023, (iv) $100,000 on December 21, 2023, (v) $100,000 on January 21, 2024, (vi) $100,000 on February 21, 2024, and (vii) all remaining amounts owed under the 2023 FirstFire Note on the maturity date (each of the aforementioned payments are an ~~Acenzia promissory note~~“Amortization Payment”). If the Company fails to make any Amortization Payment, then FirstFire shall have the right to convert the amount of such respective Amortization Payment into shares of common stock as provided in the 2023 FirstFire Note at the lesser of (i) the then applicable conversion price under the 2023 FirstFire Note or (ii) 85% of the lowest VWAP of the Company’s common stock on any trading day during the five trading days prior to the respective conversion date.

The Company may prepay the 2023 FirstFire Note at any time prior to the date that an event of default (as provided in the 2023 FirstFire Note) occurs at an amount equal to the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $750 for administrative fees. The 2023 FirstFire Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2023 FirstFire Note, the 2023 FirstFire Warrant, or SPA.

Upon the occurrence of any event of default, the 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an ~~aggregate~~amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125% (the “Default Amount”). Upon the occurrence of an Event of Default, additional interest will accrue from the date of the Event of Default at the rate equal to the lower of 16% per annum or the highest rate permitted by law.

The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $0.25 per share, subject to adjustment as provided in the 2023 FirstFire Warrant. The 2023 FirstFire Warrant also contains certain cashless exercise provisions as well as price protection provisions providing for adjustment of the number of shares of common stock issuable upon exercise of the 2023 FirstFire Warrants and the exercise price in case of future dilutive offerings, subject to certain customary exempt transactions.

As additional consideration for the purchase of the 2023 FirstFire Note and pursuant to the terms of the SPA, on March 22, 2023, the Company issued 955,000 restricted shares of the Company’s common stock (the “Commitment Shares”) to FirstFire at closing. The SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the Commitment Shares as well as the shares of common stock underlying the 2023 FirstFire Note and the 2023 FirstFire Warrant. In addition to the beneficial ownership limitations provided in the 2023 FirstFire Note and the 2023 FirstFire Warrant, the sum of the number of shares of common stock that may be issued under the SPA (including the Commitment Shares), the 2023 FirstFire Note, and 2023 FirstFire Warrant shall be limited to 10,000,000 shares as further described in the SPA, unless shareholder approval to exceed such limitation is obtained by the Company.

On April 21, 2023, the Company made a monthly interest-only payment to FirstFire in the amount of ~~$5,300,000, including all principal and interest owed.~~$5,730.

~~Restricted Stock Issuance for Independent Contractor Agreement~~RC Consulting Group SPA & Unsecured $70 Million Note

On ~~July 5, 2022,~~April 26, 2023, the Company entered into a securities purchase agreement (the “RC SPA”), dated as of April 26, 2023, with RC Consulting Group LLC in favor of SCP Tourbillion Monaco or registered assigns (the “RC Noteholder”), pursuant to which the Company issued ~~50,000 restricted~~an unsecured 15-year promissory note to the RC Noteholder (the “RC Note”) with a maturity date of April 26, 2038, in the principal sum of $70,000,000, which amount represents the $57,000,000 purchase price plus a yield (non-compounding) of 1.52% (zero coupon) per annum from April 26, 2023 until the same becomes due and payable as provided in the RC Note. The RC Note may be prepaid as set forth in the RC Note and ranks pari passu with all unsecured indebtedness of the Company.

The RC Note contains customary covenants for a transaction of this type. Among other things, so long as the RC Note is outstanding, the Company will not enter into any transaction or arrangement structured in accordance with, based upon, or related or pursuant to, in whole or in part, Section 3(a)(10) of the Securities Act of 1933, as amended (a “3(a)(10) Transaction”). In the event that the Company does enter into, or makes any issuance of common stock related to a 3(a)(10) Transaction while the RC Note is outstanding, a liquidated damages charge of 25% of the outstanding principal balance of the RC Note, but not less than $1,000,000, will be assessed and will become immediately due and payable to the RC Noteholder at its election in the form of a cash payment or added to the balance of the RC Note (under the RC Noteholder’s and the Company’s expectation that this amount will tack back to the date of issuance of the RC Note).

The RC Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the RC SPA or the RC Note.

Upon the occurrence of any Event of Default (as defined in the RC Note), the RC Note will become immediately due and payable, and the Company will pay to the RC Noteholder, in full satisfaction of its obligations thereunder, an amount equal to the principal amount then outstanding plus accrued interest (including any default interest) through the date of full repayment multiplied by 125% (collectively, the “Default Amount”), as well as all costs, including, without limitation, legal fees and expenses, of collection, all without demand, presentment or notice.

The RC SPA contains customary covenants, representations and warranties for a transaction of this type.

During the six month period ended February 28, 2023, the Company issued 1,310,000 shares of common stock ~~as consideration~~to certain warrant holders upon exercise of their warrants issued pursuant to the prospectus that forms a part of the Company’s Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022 (the “S-1 Warrants”). Subsequent to the six month period ended February 28, 2023, the Company issued 3,200,000 shares of common stock to certain warrant holders upon exercise of their warrants related to the S-1 Warrants for an ~~Independent Contractor Agreement.~~aggregate of 4,510,000 shares issued since the Company’s Registration Statement on Form S-1 (File No. 333-267401) was declared effective by the SEC on October 13, 2022

During the six month period ended February 28, 2023, the Company issued an aggregate of 93,109,398 shares of common stock to certain note holders upon conversion of their notes. Subsequent to the period ended February 28, 2023, the Company issued an aggregate of 1,075,942 shares of common stock to certain note holders upon conversion of their notes. As of March 31, 2023, (i) the principal balance owed by the Company to Hudson Bay pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to Hudson Bay is $0, (ii) the principal balance owed by the Company to CVI pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to CVI is $0; and (iii) the principal balance owed by the Company to Jefferson pursuant to the secured convertible note, dated as of November 17, 2021, as amended, issued by the Company to Jefferson is $0.

For the three months ended ~~May 31, 2022~~February 28, 2023 compared to the three months ended ~~May 31, 2021~~February 28, 2022

Revenues for the three months ended ~~May 31, 2022~~February 28, 2023 were ~~$13,851,883,~~$2,556,509, representing ~~an increase~~a decrease of ~~$11,470,909,~~$312,714, or ~~481.8%~~11%, from ~~$2,380,974~~$2,869,223 for the same period in ~~2021.~~2022. The ~~increase~~decrease in revenue is principally due to ~~an increase~~the decrease in outsourced product sales and IoNovo ~~Iodine which resulted in an increase in revenue of $9,730,236.~~Iodine. Acenzia’s and Terragenx’s revenue for the three months ended ~~May 31, 2022~~February 28, 2023 was ~~$645,588~~$458,920 and ~~$1,275,690,~~$32,167, respectively. Revenue from our healthcare services ~~decreased~~increased by ~~7.6%~~9% when comparing the revenue for the three months ended ~~May 31, 2022~~February 28, 2023 to the same period in ~~2021 primarily due to a COVID-19 surge in Ontario province Canada and COVID-19 staffing related shortages limiting clinic and eldercare patient-practitioner direct personal interaction.~~2022.

Cost of revenues for the three months ended ~~May 31, 2022~~February 28, 2023 were ~~$11,443,001,~~$1,585,606, representing ~~an increase~~a decrease of ~~$10,342,485~~$67,263, or ~~939.8%~~4%, from ~~$1,100,516~~$1,652,869 for the same period in ~~2021. The increase in cost of revenues is principally due the increase in revenue as described above.~~2022. Cost of revenues as a percentage of revenue for our healthcare and product sales segments was ~~57.3%~~62% and ~~87.4%~~63%, respectively, for the three months ended ~~May 31, 2022.~~February 28, 2023. The cost of revenue for our healthcare and product sales segment was ~~46.2%~~59% and 54%, respectively for same period in ~~2021.~~2022. The increase in cost of revenues as a percentage of revenue for our ~~healthcare~~product sales segment is principally due to ~~COVID-19 wage subsidies received from~~ the ~~government~~increase in ~~2021.~~product costs.

Operating costs for the three months ended ~~May 31, 2022~~February 28, 2023 were ~~$3,611,628,~~$2,757,713, representing ~~an increase~~a decrease of ~~$1,929,198,~~$579,317, or ~~114.7%~~17%, from ~~$1,682,430~~$3,337,030 for the same period in ~~2021.~~2022. The ~~increase~~decrease in operating costs is principally due to the ~~increase~~decrease in overhead expenses ~~associated with the operations of Acenzia, PRO-DIP,~~ and ~~Terragenx which was approximately $952,000 for the three months ended May 31, 2022. In subsequent quarters, this increase in overhead expenses associated with Acenzia, PRO-DIP,~~depreciation and Terragenx is projected to decrease as the Company integrates and consolidates operations. In addition, common stock issued for services increased by $276,828 for the three months ended May 31, 2022 compared to the same period in 2021. Also, an increase in legal and professional fees contributed to the increase in operating expenses.amortization.

Interest expense for the three months ended ~~May 31, 2022~~February 28, 2023 was ~~$513,398,~~$123,866, representing ~~an increase~~a decrease of ~~$491,697,~~$1,102,316, or ~~2,266%~~90%, from ~~$21,701~~$1,226,182 for the same period in ~~2021.~~2022. The ~~increase~~decrease is due to ~~issuance~~cash payment and conversion of convertible notes ~~for $1,875,000 in November 2021 and $16,666,666 in December 2021.~~to common stock as of February 28, 2023.

Amortization of debt discount for the three months ended ~~May 31, 2022~~February 28, 2023 was ~~$2,133,890,~~$2,740,349, representing an increase of ~~$2,133,890~~$1,277,327 from $0$1,463,022 for the same period in ~~2021.~~2022. The increase is due to amortization of the debt discounts associated with the convertible notes issued in November 2021 and December 2021.

Foreign currency transaction ~~gains~~gain for the three months ended ~~May 31, 2022~~February 28, 2023 was ~~$97,654~~$3,620 compared to $0foreign currency transaction loss of $66,814 for the same period in ~~2021.~~2022. Acenzia and Terragenx both have outstanding debt recorded on their books that is payable in US Dollars. The exchange rate between the Canadian Dollar and the US Dollar decreased during the third fiscal quarter of 2022; therefore, creating a foreign currency transaction gain as it will require more Canadian Dollars to repay the debt.

Net loss attributed to Novo Integrated Sciences, Inc. for the three months ended ~~May 31, 2022~~February 28, 2023 was ~~$3,810,054,~~$4,621,355, representing an ~~increase~~decrease of ~~$3,398,867,~~$183,812, or ~~827%~~4%, from ~~$411,187~~$4,805,167 for the same period in ~~2021.~~2022. The ~~increase~~decrease in net loss is principally due to ~~(i) an increase~~the decrease in overhead expenses associated with the operations of Acenzia, PRO-DIP, and Terragenx which was approximately $952,000 for the three months ended May 31, 2022, (ii) common stock issued for services of $314,000; (iii) an increase in interest expense and (iv) an increase in amortization of debt discounts.operating expenses.

For the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 compared to the ~~nine~~six months ended ~~May 31, 2021~~February 28, 2022

Revenues for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 were ~~$19,883,033,~~$5,975,789, representing ~~an increase~~a decrease of ~~$13,270,659,~~$55,361, or ~~200.7%~~1%, from ~~$6,612,374~~$6,031,150 for the same period in ~~2021.~~2022. The ~~increase~~decrease in revenue is principally due to ~~an increase~~the decrease in outsourced product sales and IoNovo ~~iodine and the acquisition of both Acenzia, Inc. in June 2021 and Terragenx in November 2021. Sales of outsourced products and IoNovo Iodine resulted in an increase in revenue of $9,730,236.~~Iodine. Acenzia’s and ~~Terragenx’~~Terragenx’s revenue for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 was ~~$2,376,785~~$1,236,149 and ~~$1,521,348,~~$41,324, respectively. Revenue from our healthcare services ~~decreased~~increased by ~~5.4%~~0.1% when comparing the revenue for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 to the same period in ~~2021.~~2022.

Cost of revenues for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 were ~~$14,991,331,~~$3,265,353, representing ~~an increase~~a decrease of ~~$11,222,311~~$282,977, or ~~297.8%~~8%, from ~~$3,769,020~~$3,548,330 for the same period in ~~2021. The increase in cost of revenues is principally due the increase in revenue as described above.~~2022. Cost of revenues as a percentage of revenue for our healthcare and product sales segments was ~~60.0%~~62% and ~~82.4%~~59%, respectively, for the ~~nine~~six months ended ~~May 31, 2022. Cost~~February 28, 2023. The cost of revenue for our healthcare and product sales segment was ~~57.0%~~62% and 53%, respectively for same period in 2022. The increase in cost of revenues as a percentage of revenue for our product sales segment is principally due to the increase in product costs.

Operating costs for the six months ended February 28, 2023 were $6,739,206, representing an increase of $772,051, or 13%, from $5,967,155 for the same period in ~~2021.~~

~~Operating costs for the nine months ended May 31, 2022 were $9,578,783, representing an increase of $4,249,789, or 79.7%, from $5,328,994 for the same period in 2021.~~2022. The increase in operating costs is principally due to the increase in overhead expenses associated with the operations of Acenzia, PRO-DIP, and Terragenx which was approximately ~~$2,438,000~~$1,682,966 for the ~~nine~~six months ended ~~May 31, 2022.~~February 28, 2023. In subsequent quarters, this increase in overhead expenses associated with ~~the operations of~~ Acenzia, PRO-DIP, and Terragenx is projected to decrease as the Company integrates and consolidates operations. ~~In addition, common stock issued for services increased by $475,578 for the nine months ended May 31, 2022 compared to the same period in 2021.~~ Also, an increase in legal and professional fees contributed to the increase in operating ~~expenses for the nine months ended May 31, 2022.~~expenses.

Interest expense for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 was ~~$1,808,310,~~$291,109, representing ~~an increase~~a decrease of ~~$1,739,720,~~$1,003,803, or ~~2,536%~~78%, from ~~$68,590~~$1,294,912 for the same period in ~~2021.~~2022. The ~~increase~~decrease is due to ~~issuance~~cash payment and conversion of convertible notes ~~for $1,875,000 in November 2021 and $16,666,666 in December 2021, plus penalty interest paid in connection with the early repayment~~to common stock as of ~~a note payable of approximately $4,415,000.~~February 28, 2023.

Amortization of debt discount for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 was ~~$3,654,752,~~$4,230,862, representing an increase of ~~$3,654,752~~$2,710,000 from $0$1,520,862 for the same period in ~~2021.~~2022. The increase is due to amortization of the debt discounts associated with the convertible notes issued in November 2021 and December 2021.

Foreign currency transaction losses for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 was ~~$303,714~~$35,681 compared to $0$401,368 for the same period in ~~2021.~~2022. Acenzia and Terragenx both have outstanding debt recorded on their books that is payable in US Dollars. The exchange rate between the Canadian Dollar and the US Dollar ~~has~~ decreased ~~since August 31, 2021;~~during the third fiscal quarter of 2022; therefore, creating a foreign currency transaction ~~loss~~gain as it will require more Canadian Dollars to repay the debt.

Net loss attributed to Novo Integrated Sciences, Inc. for the ~~nine~~six months ended ~~May 31, 2022~~February 28, 2023 was ~~$10,421,808,~~$8,556,768, representing an increase of ~~$7,899,281,~~$1,945,014, or ~~313.1%~~29%, from ~~$2,522,527~~$6,611,754 for the same period in ~~2021.~~2022. The increase in net loss is principally due to (i) ~~an increase in foreign currency transaction losses, (ii)~~ an increase in overhead expenses associated with the operations of Acenzia, PRO-DIP, and Terragenx which was approximately ~~$2,438,000~~$1,682,966 for the ~~nine~~six months ended ~~May 31, 2022, (iii)~~February 28, 2023, and (ii) an ~~increase in interest expense and (iv) in~~ increase in amortization of debt discounts.

As shown in the accompanying unaudited condensed consolidated financial statements, for the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, the Company had a net loss of ~~$10,428,624.~~$8,581,898.

During the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, the Company used cash in operating activities of ~~$6,559,907~~$1,156,821 compared to ~~$279,280~~$3,009,732 of cash used in operating activities for the same period in ~~2021.~~2022. The principal reason for the ~~increase~~decrease in cash used in operating activities is the net loss incurred and the changes in noncash expenses and changes in operating asset and liability accounts.

During the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, the Company ~~provided~~used cash from investing activities of ~~$162,654~~$nil compared to cash used from investing activities of ~~$681,409~~$163,245 for the same period in ~~2021.~~2022. The principal reason for the change is due to the ~~payment of other receivable~~no property and equipment purchases in ~~2022~~the six months ended February 28, 2023 compared to ~~amounts loaned for other receivables~~the same period in ~~2021.~~2022.

During the ~~nine~~six months ended ~~May 31, 2022,~~February 28, 2023, the Company ~~provided~~used cash ~~from~~in financing activities of ~~$10,802,477~~$604,704 compared to ~~$7,162,046~~$10,839,716 of cash provided by financing activities for the same period in ~~2021.~~2022. The principal reason for the ~~increase~~decrease in cash provided by financing activities was the repayment of convertible notes of $2,977,778, repayment of finance leases of $4,299, offset by proceeds received from related parties of $6,138, the sale of units, net of issuance costs of $1,795,000, proceeds from exercise of warrants of $131,000 and proceeds from issuance of convertible notes ~~payable in November 2021 and December 2021~~of $445,235. In the same period for ~~net proceeds of $15,270,000, offset by the repayment of notes payable of $4,430,794. In 2021,~~2022, the Company received ~~$7,327,580~~$15,270,000 from the ~~sale~~issuance of ~~common stock.~~convertible notes.

In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. On March 17, 2020, as a result of COVID-19 pandemic having been reported throughout both Canada and the United States, certain national, provincial, state and local governmental authorities issued proclamations and/or directives aimed at minimizing the spread of COVID-19. Accordingly, on March 17, 2020, the Company closed all corporate clinics for all in-clinic non-essential services to protect the health and safety of its employees, partners, and patients. Commencing in May 2020, the Company was able to begin providing some services, and was fully operational again in June 2020. As of ~~May 31, 2022,~~February 28, 2023, all corporate clinics were open and fully operational, with staffing shortages in some facilities due to ongoing COVID-19 residual impact, while following all mandated guidelines and protocols from Health Canada, the Ontario Ministry of Health, and the respective disciplines’ regulatory Colleges to ensure a safe treatment environment for our staff and clients, and our eldercare operations are fully operational. In addition, Acenzia, Terragenx, PRO-DIP, and CCI are open and fully operational, with staffing shortages due to ongoing COVID-19 residual impact, while following all local, state, provincial, and national guidelines and protocols related to minimizing the spread of the COVID-19 pandemic.

Canadian federal and provincial COVID-19 governmental proclamations and directives, including interprovincial travel restrictions, have presented unprecedented challenges to launching our Harvest Gold Farms and Kainai Cooperative joint ventures during the period ended ~~May 31, 2022.~~February 28, 2023. Accordingly, the Company has decided to delay commencing the projects until the ~~2022~~2023 grow season. These joint ventures relate to the development, management, and arrangement of medicinal farming projects involving industrial hemp for medicinal ~~Cannabidiol~~cannabidiol (CBD) applications.

For the ~~quarter~~three month period ended ~~May 31, 2022,~~February 28, 2023, the Company’s total revenue from all clinic and eldercare related contracted services was ~~$2,199,889,~~$2,034,154, representing a ~~7.6% decrease~~9% increase of ~~$181,085~~$160,577 compared to ~~$2,380,974~~$1,873,577 during the same period in ~~2021. This decrease is primarily due to a COVID-19 surge in Ontario province Canada and COVID-19 staffing related shortages limiting~~2022.

For the six month period ended February 28, 2023, the Company’s total revenue from all clinic and eldercare ~~patient-practitioner direct personal interaction.~~related contracted services was $4,055,368, representing a 0.1% increase of $2,168 compared to $4,053,200 during the same period in 2022.

While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including, but not limited to, (i) the duration of the COVID-19 outbreak and additional variants that may be identified, (ii) new information which may emerge concerning the severity of the COVID-19 pandemic, and (iii) any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic, and reduced operations.

Our capital requirements going forward will consist of financing our operations until we are able to reach a level of revenues and gross margins adequate to equal or exceed our ongoing operating expenses. We do not have any credit agreement or source of liquidity immediately available to us.

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

We believe that the following critical policies affect our more significant judgments and estimates used in preparation of our financial statements.

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the ~~condensed~~ consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful accounts, allowance for slow moving and obsolete inventory, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

The Company has not changed its estimate for the useful lives of its property and equipment, but would expect that a decrease in the estimated useful lives of property and equipment of 20% would result in an annual increase to depreciation expense of approximately ~~$148,000,~~$169,137, and an increase in the estimated useful lives of property and equipment of 20% would result in an annual decrease to depreciation expense of approximately ~~$99,000.~~$112,758.

The Company’s intangible assets are being amortized over their estimated useful lives as follows:

The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. The Company has not changed its estimate for the useful lives of its intangible assets but would expect that a decrease in the estimated useful lives of intangible assets of 20% would result in an annual increase to amortization expense of approximately ~~$672,000,~~$500,477, and an increase in the estimated useful lives of intangible assets of 20% would result in an annual decrease to amortization expense of approximately ~~$448,000.~~$333,651.

The Company applies the provisions of ~~the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”)~~ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statements of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia, Inc. (“Acenzia”) during fiscal year ended August 31, 2021, and ~~12858461~~1285 Canada, ~~Corp.,~~and Fairway Physiotherapy and Sports Injury Clinic ~~and Clinical Consultants International LLC~~(“Fairway”) during fiscal year ~~ending~~ended August 31, 2022. As of August 31, 2022, the Company performed the required impairment reviews and determined that an impairment charge of $1,357,043 related to the goodwill for Acenzia was necessary. The Company determined that the carrying value was in excess of the expected fair value of discounted cash flows based on the current market and business environments, resulting in the need for impairment. The impairment was determined based on the discounted cash flow valuation model and the projected future cash flows of the underlying business. Based on its review at February 28, 2023, the Company believes there was no additional impairment of its goodwill.

Accounts Receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends, and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. The Company has not changed its methodology for estimating allowance for doubtful accounts and historically the change in estimate has not been significant to the Company’s condensed consolidated financial statements. If there is a deterioration of the Company’s customers’ ability to pay or if future write-offs of receivables differ from those currently anticipated, the Company may have to adjust its allowance for doubtful accounts, which would affect earnings in the period the adjustments are made.

Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.

The Company’s revenue recognition reflects the updated accounting policies as per the requirements of ~~the FASB’s Accounting Standards Update (“ASU”)~~ASU No. 2014-09, Revenue from Contracts with Customers (“(“Topic 606”). As sales are and have been primarily from providing healthcare services the Company has no significant post-delivery obligations.

These five elements, as applied to the Company’s revenue category, are summarized below:

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar and the functional currency of the Parent is the United States dollar. Translation gains (losses) are classified as an item of other comprehensive income in the stockholders’ equity section of the condensed consolidated balance ~~sheets.~~sheet.

Recent accounting pronouncements issued by the FASB, the American Institute of Certified Public Accountants and the SEC did not or are not believed by management to have a material effect on the Company’s condensed consolidated financial statements.

The Company’s Chief Executive Officer and Principal Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of ~~May 31, 2022.~~February 28, 2023. Based upon such evaluation, the Chief Executive Officer and Principal Financial Officer have concluded that, as of ~~May 31, 2022,~~February 28, 2023, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the ~~fiscal quarter~~period ended ~~May 31, 2022~~February 28, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Except as set forth herein, as of the date of this Quarterly Report on Form 10-Q, there are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or which our property is the subject. In addition, none of our officers, directors, affiliates or 5% stockholders (or any associates thereof) is a party adverse to us, or has a material interest adverse to us, in any material proceeding.

On ~~March 18, 2022,~~January 5, 2023, the Company issued ~~50,000~~1,159,348 shares of common stock pursuant to exchange for shares of common stock underlying certain warrants.

On January 25, 2023, the Company issued 3,202,019 restricted shares of common stock ~~as consideration~~issued for ~~an Independent Contractor~~NHL Exchangeable Shares under the terms and conditions of a Share Exchange Agreement ~~dated November 16, 2020.~~which closed on June 24, 2021.

On ~~March 18, 2022,~~February 24, 2023, the Company issued ~~25,000 restricted~~955,000 shares of common stock ~~as consideration for an Independent Contractor Agreement, dated November 16, 2020.~~

~~On April 7, 2022, the Company issued 800,000 restricted shares of common stock as consideration for~~pursuant to a ~~Membership Interest~~Securities Purchase Agreement, dated ~~March 17, 2022 and closed on April 5, 2022.~~

~~On May 2, 2022, the Company issued 50,000 restricted shares of common stock as consideration for a Consulting Agreement, dated April 20, 2022.~~

~~On May 11, 2022, the Company issued 225,000 restricted shares of common stock as consideration for a Share Exchange Agreement, dated May 28, 2021 and closed on June 24, 2021.~~February 23, 2023.

The above sales were made pursuant to an exemption from registration as set forth in Regulation S under the Securities Act, Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

There have been no defaults in any material payments during the covered period.

(b) There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors since the Company last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

PART I – FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3331

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4750

Item 4.	Controls and Procedures	4750

PART II – OTHER INFORMATION		4750

Item 1.	Legal Proceedings	4750

Item 1A.	Risk Factors	4750

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4750

Item 3.	Defaults Upon Senior Securities	4850

Item 4.	Mine Safety Disclosures	4850

Item 5.	Other Information	4851

Item 6.	Exhibits	4851

Signatures		4952

	May 31,			May 31,			May 31,			May 31,
	Three Months Ended						Nine Months Ended
	May 31,			May 31,			May 31,			May 31,
	2022			2021			2022			2021
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Revenues	$	13,851,883		$	2,380,974		$	19,883,033		$	6,612,374

Cost of revenues		11,443,001			1,100,516			14,991,331			3,769,020

Gross profit		2,408,882			1,280,458			4,891,702			2,843,354

Operating expenses:
Selling expenses		9,802			2,381			36,340			4,226
General and administrative expenses		3,601,826			1,680,049			9,542,443			5,324,768
Total operating expenses		3,611,628			1,682,430			9,578,783			5,328,994

Loss from operations		(1,202,746	)		(401,972	)		(4,687,081	)		(2,485,640	)

Non operating income (expense)
Interest income		8,355			8,402			25,233			25,265
Interest expense		(513,398	)		(21,701	)		(1,808,310	)		(68,590	)
Amortization of debt discount		(2,133,890	)		-			(3,654,752	)		-
Foreign currency transaction gains (losses)		97,654			-			(303,714	)		-
Total other income (expense)		(2,541,279	)		(13,299	)		(5,741,543	)		(43,325	)

Loss before income taxes		(3,744,025	)		(415,271	)		(10,428,624	)		(2,528,965	)

Income tax expense		-			-			-			-

Net loss	$	(3,744,025	)	$	(415,271	)	$	(10,428,624	)	$	(2,528,965	)

Net income (loss) attributed to noncontrolling interest		66,029			(4,084	)		(6,816	)		(6,438	)

Net loss attributed to Novo Integrated Sciences, Inc.	$	(3,810,054	)	$	(411,187	)	$	(10,421,808	)	$	(2,522,527	)

Comprehensive loss:
Net loss		(3,744,025	)		(415,271	)		(10,428,624	)		(2,528,965	)
Foreign currency translation gain		13,711			123,521			24,916			176,349
Comprehensive loss:	$	(3,730,314	)	$	(291,750	)	$	(10,403,708	)	$	(2,352,616	)

Weighted average common shares outstanding - basic and diluted		29,817,999			25,298,866			28,498,414			24,192,998

Net loss per common share - basic and diluted	$	(0.13	)	$	(0.02	)	$	(0.37	)	$	(0.10	)

	February 28,			February 28,			February 28,			February 28,
	Three Months Ended						Six Months Ended
	February 28,			February 28,			February 28,			February 28,
	2023			2022			2023			2022
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Revenues	$	2,556,509		$	2,869,223		$	5,975,789		$	6,031,150

Cost of revenues		1,585,606			1,652,869			3,265,353			3,548,330

Gross profit		970,903			1,216,354			2,710,436			2,482,820

Operating expenses:
Selling expenses		707			26,370			8,039			26,538
General and administrative expenses		2,757,006			3,310,660			6,731,167			5,940,617
Total operating expenses		2,757,713			3,337,030			6,739,206			5,967,155

Loss from operations		(1,786,810	)		(2,120,676	)		(4,028,770	)		(3,484,335	)

Non-operating income (expense)
Interest income		2,243			8,490			4,524			16,878
Interest expense		(123,866	)		(1,226,182	)		(291,109	)		(1,294,912	)
Amortization of debt discount		(2,740,349	)		(1,463,022	)		(4,230,862	)		(1,520,862	)
Foreign currency transaction gain (loss)		3,620			(66,814	)		(35,681	)		(401,368	)
Total other income (expense)		(2,858,352	)		(2,747,528	)		(4,553,128	)		(3,200,264	)

Loss before income taxes		(4,645,162	)		(4,868,204	)		(8,581,898	)		(6,684,599	)

Income tax expense		-			-			-			-

Net loss	$	(4,645,162	)	$	(4,868,204	)	$	(8,581,898	)	$	(6,684,599	)

Net loss attributed to noncontrolling interest		(23,807	)		(63,037	)		(25,130	)		(72,845	)

Net loss attributed to Novo Integrated Sciences, Inc.		(4,621,355	)	$	(4,805,167	)		(8,556,768	)	$	(6,611,754	)

Comprehensive loss:
Net loss		(4,645,162	)		(4,868,204	)		(8,581,898	)		(6,684,599	)
Foreign currency translation (loss) gain		(196,683	)		115,093			(617,665	)		10,705
Comprehensive loss:	$	(4,841,845	)	$	(4,753,111	)	$	(9,199,563	)	$	(6,673,894	)

Weighted average common shares outstanding - basic and diluted		79,334,919			28,740,700			56,469,365			27,827,686

Net loss per common share - basic and diluted	$	(0.06	)	$	(0.17	)	$	(0.15	)	$	(0.24	)

	Shares		Amount		Capital			Be Issued			Income			Deficit			Equity			Interest			Equity
																	Total
					Additional			Common			Other						Novo
	Common Stock				Paid-in			Stock To			Comprehensive			Accumulated			Stockholders’			Noncontrolling			Total
	Shares		Amount		Capital			Be Issued			Income			Deficit			Equity			Interest			Equity
Balance, August 31, 2021		26,610,144	$	26,610	$	54,579,396		$	9,236,607		$	991,077		$	(20,969,274	)	$	43,864,416		$	(60,261	)	$	43,804,155

Common stock for services		35,000		35		64,715			-			-			-			64,750			-			64,750
Common stock issued as collateral and held in escrow		2,000,000		2,000		(2,000	)		-			-			-			-			-			-
Common stock to be issued for purchase of Terragenx		-		-		-			983,925			-			-			983,925			97,311			1,081,236
Common stock to be issued for purchase of Mullin assets		-		-		-			188,925			-			-			188,925			-			188,925
Value of warrants issued with convertible notes		-		-		295,824			-			-			-			295,824			-			295,824
Fair value of stock options		-		-		154,135			-			-			-			154,135			-			154,135
Foreign currency translation loss		-		-		-			-			(103,533	)		-			(103,533	)		(855	)		(104,388	)
Net loss		-		-		-			-			-			(1,806,587	)		(1,806,587	)		(9,808	)		(1,816,395	)

Balance, November 30, 2021		28,645,144		28,645		55,092,070			10,409,457			887,544			(22,775,861	)		43,641,855			26,387			43,668,242

Common stock for services		240,000		240		297,760			-			-			-			298,000			-			298,000
Value of warrants issued with convertible notes		-		-		5,257,466			-			-			-			5,257,466			-			5,257,466
Fair value of stock options		-		-		44,427			-			-			-			44,427			-			44,427
Foreign currency translation gain		-		-		-			-			114,738			-			114,738			355			115,093
Net loss		-		-		-			-			-			(4,805,167	)		(4,805,167	)		(63,037	)		(4,868,204	)

Balance, February 28, 2022		28,885,144		28,885		60,691,723			10,409,457			1,002,282			(27,581,028	)		44,551,319			(36,295	)		44,515,024

Common stock for services		125,000		125		313,875			-			-			-			314,000			-			314,000
Common stock for conversion of convertible notes		623,929		624		1,247,225			-			-			-			1,247,849			-			1,247,849
Common stock for acquisition		800,000		800		1,703,200			-			-			-			1,704,000			-			1,704,000
Common stock to be issued for acquisitions		-		-		-			260,625			-			-			260,625			25,402			286,027
Issuance of common stock to be issued		225,000		225		573,525			(573,750	)		-			-			-			-			-
Fair value of stock options		-		-		91,330			-			-			-			91,330			-			91,330
Foreign currency translation gain		-		-		-			-			13,711			-			13,711			51			13,762
Net loss		-		-		-			-			-			(3,810,054	)		(3,810,054	)		66,029			(3,744,025	)

Balance, May 31, 2022		30,659,073	$	30,659	$	64,620,878		$	10,096,332		$	1,015,993		$	(31,391,082	)	$	44,372,780		$	55,187		$	44,427,967

Balance, August 31, 2020		23,466,236	$	23,466	$	44,905,454		$	-		$	1,199,696		$	(16,507,127	)	$	29,621,489		$	(49,859	)	$	29,571,630

Common stock issued for cash		21,905		22		91,978			-			-			-			92,000			-			92,000
Common stock issued for services		65,000		65		247,935			-			-			-			248,000			-			248,000
Foreign currency translation gain		-		-		-			-			10,596			-			10,596			(225	)		10,371
Net loss		-		-		-			-			-			(771,470	)		(771,470	)		(1,633	)		(773,103	)

Balance, November 30, 2020		23,553,141		23,553		45,245,367			-			1,210,292			(17,278,597	)		29,200,615			(51,717	)		29,148,898

Exercise of stock options		7,500		8		11,992			-			-			-			12,000			-			12,000
Common stock issued for intellectual property		240,000		240		875,760			-			-			-			876,000			-			876,000
Common stock to be issued for services rendered		-		-		-			375,000			-			-			375,000			-			375,000
Rounding due to stock split		957		1		(1	)		-			-			-			-			-			-
Fair value of vested stock options		-		-		22,215			-			-			-			22,215			-			22,215
Foreign currency translation gain		-		-		-			-			42,232			-			42,232			(965	)		41,267
Net loss		-		-		-			-			-			(1,339,870	)		(1,339,870	)		(721	)		(1,340,591	)

Balance, February 28, 2021		23,801,598		23,802		46,155,333			375,000			1,252,524			(18,618,467	)		29,188,192			(53,403	)		29,134,789

Common stock for services		100,000		100		374,900			(375,000	)		-			-			-			-			-
Common stock issued for acquisition		189,796		190		430,647			-			-			-			430,837			-			430,837
Common stock issued for services rendered		9,913		9		37,163			-			-			-			37,172			-			37,172
Common stock issued for cash, net of offering costs		2,388,050		2,388		7,233,192			-			-			-			7,235,580			-			7,235,580
Fair value of vested stock options		-		-		66,640			-			-			-			66,640			-			66,640
Foreign currency translation gain		-		-		-			-			123,521			-			123,521			(3,143	)		120,378
Net loss		-		-		-			-			-			(411,187	)		(411,187	)		(4,084	)		(415,271	)

Balance, May 31, 2021		26,489,357	$	26,489	$	54,297,875		$	-		$	1,376,045		$	(19,029,654	)	$	36,670,755		$	(60,630	)	$	36,610,125

					Additional			Common			Other						Novo
	Common Stock				Paid-in			Stock To			Comprehensive			Accumulated			Stockholders’			Noncontrolling			Total
	Shares		Amount		Capital			Be Issued			Income			Deficit			Equity			Interest			Equity
Balance, August 31, 2022		31,180,603	$	31,181	$	66,056,824		$	9,474,807		$	560,836		$	(53,818,489	)	$	22,305,159		$	(257,588	)	$	22,047,571
Units issued for cash, net of offering costs		4,000,000		4,000		1,791,000			-			-			-			1,795,000			-			1,795,000
Issuance of common stock to be issued		36,222		36		92,330			(92,366	)		-			-			-			-			-
Cashless exercise of warrants		4,673,986		4,674		1,134,376			-			-			-			1,139,050			-			1,139,050
Fair value of stock options		-		-		60,887			-			-			-			60,887			-			60,887
Foreign currency translation loss		-		-		-			-			(417,008	)		-			(417,008	)		(3,974	)		(420,982	)
Net loss		-		-		-			-			-			(3,935,413	)		(3,935,413	)		(1,323	)		(3,936,736	)
Balance, November 30, 2022		39,890,811	$	39,891	$	69,135,417		$	9,382,441		$	143,828		$	(57,753,902	)	$	20,947,675		$	(262,885	)	$	20,684,790

Share issuance for convertible debt settlement		93,109,398		93,110		8,992,941			-			-			-			9,086,051			-			9,086,051
Cashless exercise of warrants		1,159,348		1,159		281,374			-			-			-			282,533			-			282,533
Exercise of warrants for cash		1,310,000		1,310		129,690			-			-			-			131,000			-			131,000
Issuance of common stock to be issued		3,202,019		3,201		8,161,947			(8,165,148	)		-			-			-			-			-
Shares issued with convertible notes		955,000		955		82,008			-			-			-			82,963			-			82,963
Value of warrants issued with convertible notes		-		-		86,327			-			-			-			86,327			-			86,327
Fair value of stock options		-		-		60,887			-			-			-			60,887			-			60,887
Extinguishment of derivative liability due to conversion		-		-		1,390,380			-			-			-			1,390,380			-			1,390,380
Foreign currency translation loss		-		-		-			-			(195,821	)		-			(195,821	)		(862	)		(196,683	)
Net loss		-		-		-			-			-			(4,621,355	)		(4,621,355	)		(23,807	)		(4,645,162	)
Balance, February 28, 2023		139,626,576	$	139,626	$	88,320,971		$	1,217,293		$	(51,993	)	$	(62,375,257	)	$	27,250,640		$	(287,554	)	$	26,963,086

Balance, August 31, 2021		26,610,144	$	26,610	$	54,579,396		$	9,236,607		$	991,077		$	(20,969,274	)	$	43,864,416		$	(60,261	)	$	43,804,155
Common stock for services		35,000		35		64,715			-			-			-			64,750			-			64,750
Common stock issued as collateral and held in escrow		2,000,000		2,000		(2,000	)		-			-			-			-			-			-
Common stock to be issued for purchase of Terragenx		-		-		-			983,925			-			-			983,925			97,311			1,081,236
Common stock to be issued for purchase of Mullin assets		-		-		-			188,925			-			-			188,925			-			188,925
Value of warrants issued with convertible notes		-		-		295,824			-			-			-			295,824			-			295,824
Fair value of stock options		-		-		154,135			-			-			-			154,135			-			154,135
Foreign currency translation loss		-		-		-			-			(103,533	)		-			(103,533	)		(855	)		(104,388	)
Net loss		-		-		-			-			-			(1,806,587	)		(1,806,587	)		(9,808	)		(1,816,395	)

Balance, November 30, 2021		28,645,144	$	28,645	$	55,092,070		$	10,409,457		$	887,544		$	(22,775,861	)	$	43,641,855		$	26,387		$	43,668,242
Balance		28,645,144	$	28,645	$	55,092,070		$	10,409,457		$	887,544		$	(22,775,861	)	$	43,641,855		$	26,387		$	43,668,242
Common stock for services		240,000		240		297,760			-			-			-			298,000			-			298,000
Value of warrants issued with convertible notes		-		-		5,257,466			-			-			-			5,257,466			-			5,257,466
Fair value of stock options		-		-		44,427			-			-			-			44,427			-			44,427
Foreign currency translation gain		-		-		-			-			114,738			-			114,738			355			115,093
Net loss		-		-		-			-			-			(4,805,167	)		(4,805,167	)		(63,037	)		(4,868,204	)

Balance, February 28, 2022		28,885,144	$	28,885	$	60,691,723		$	10,409,457		$	1,002,282		$	(27,581,028	)	$	44,551,319		$	(36,295	)	$	44,515,024
Balance		28,885,144	$	28,885	$	60,691,723		$	10,409,457		$	1,002,282		$	(27,581,028	)	$	44,551,319		$	(36,295	)	$	44,515,024

Title of each class		Trading Symbol(s)		Name of each Exchange on which Registered
Common Stock		NVOS		The Nasdaq Stock Market LLC

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

	●	First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.

	●	Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.

	●	Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

	Building	30 years
	Leasehold improvements	5 years
	Clinical equipment	5 years
	Computer equipment	3 years
	Office equipment	5 years
	Furniture and fixtures	5 years

	Land use rights	50 years (the lease period)
	~~Software license~~	7 ~~years~~
	Intellectual property	7 years
	Customer relationships	5 years
	Brand names	7 years

	APKA			EFL			Rockland			Acenzia			1285 Canada			Total
Balance, August 31, 2021	$	197,925		$	129,839		$	229,593		$	8,931,491		$	-		$	9,488,848
Goodwill acquired with purchase of business		-			-			-			-			602			602
Impairment of goodwill		-			-			-			(1,357,043	)		-			(1,357,043	)
Foreign currency translation adjustment		(7,247	)		(4,751	)		(8,405	)		(286,141	)		(19	)		(306,563	)
Balance, August 31, 2022	$	190,678		$	125,088		$	221,188		$	7,288,307		$	583		$	7,825,844
Beginning Balance	$	190,678		$	125,088		$	221,188		$	7,288,307		$	583		$	7,825,844
Foreign currency translation adjustment		(6,976	)		(4,579	)		(8,094	)		(266,705	)		(21	)		(286,375	)
Balance, February 28, 2023	$	183,702		$	120,509		$	213,094		$	7,021,602		$	562		$	7,539,469
Ending Balance	$	183,702		$	120,509		$	213,094		$	7,021,602		$	562		$	7,539,469

	●	Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

	●	Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

	●	executed contracts with the Company’s customers that it believes are legally enforceable;
	●	identification of performance obligations in the respective contract;
	●	determination of the transaction price for each performance obligation in the respective contract;
	●	allocation the transaction price to each performance obligation; and
	●	recognition of revenue only when the Company satisfies each performance obligation.

	●	Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.
	●	Product sales – revenue is recorded at the point of time of delivery

Twelve Months Ending May 31,
2023	$	2,690,018
2024		2,690,018
2025		2,690,018
2026		2,662,926
2027		2,115,863
Thereafter		19,344,015
Total	$	32,192,858

Twelve Months Ending February 28,
2024	$	2,001,908
2025		2,001,908
2026		1,694,877
2027		1,420,217
2028		1,108,057
Thereafter		8,972,653
Total	$	17,199,620

	●	Expected life of 4.0 years;
	●	Volatility of 275%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 1.23%

	●	Expected life of 0.58 years;
	●	Volatility of 148.20%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 4.55%

	●	Expected life of 3.0 years;
	●	Volatility of 300%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 0.85%

	●	Expected life of 5.0 years;
	●	Volatility of 252%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 4.09%

	●	~~35,000~~4,000,000 ~~restricted~~ shares of common stock were issued as ~~consideration~~offered by the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022, for an agreed upon purchase price of $0.50 per unit. The shares were issued on October 18, 2022. The Company sold an aggregate of 4,000,000 units for aggregate gross proceeds of $2,000,000, consisting of 4,000,000 common stock, 4,000,000 warrants with a ~~Consulting~~three-year term to purchase 4,000,000 shares of common stock at an exercise price of $0.50 per share, and ~~Services Agreement valued~~4,000,000 warrants with a five-year term to purchase 4,000,000 shares of common stock at an exercise price of $~~64,750~~0.50 per share. The Company paid a cash fee of $140,000 equal to 7.0% of the gross proceeds of the offering as well as reimbursed the agent for its accountable expenses, resulting in net proceeds to the Company of $1,795,000. The total fair value of the 8,000,000 warrants granted was estimated on the date of the grant to be $1,137,959. The fair value was determined ~~based on~~using the ~~market~~Black- Scholes pricing model with the following assumptions: expected volatility of 149.06% to 206.90%; expected dividend yield of 0%; risk-free interest rate of 2.55% to 2.89%; stock price of ~~the Company’s common stock on the date~~$0.2956; and expected life of ~~grant. The shares were issued on~~ ~~September 16, 2021~~3. to 5 years.

	●	~~2,000,000~~36,222 restricted shares of common stock as collateral to be held in escrow pursuant to the terms and conditions provided for in a certain Securities Purchase Agreement, Pledge and Security Agreement, Secured Convertible Promissory Note, and Escrow Agreement, all dated ~~November 17, 2021~~ ~~to which the Company is a guarantor for that certain senior secured convertible promissory note in the principal amount of up to $1,875,000. The shares~~ were ~~issued on November 23, 2021. The Company value these shares at $~~0 ~~since they are being held in escrow and will only be released to the convertible note holders upon certain conditions, including default on the notes.~~

	●	~~50,000~~ ~~restricted shares of common stock as consideration for a Consulting Agreement valued at $65,500. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~December 20, 2021~~.

	●	~~25,000~~ ~~restricted shares of common stock as consideration for an Independent Contractor Agreement valued at $30,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~January 24, 2022~~.

	●	~~65,000~~ ~~restricted shares of common stock as consideration for an Independent Contractor Agreement valued at $78,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~January 24, 2022~~.

	●	~~50,000~~ ~~restricted shares of common stock as consideration for a Consulting Agreement valued at $60,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~January 24, 2022~~.

	●	~~50,000~~ ~~restricted shares of common stock as consideration for a Consulting Agreement valued at $64,500. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~February 24, 2022~~.

	●	~~50,000restricted shares of common stock as consideration for an Independent Contractor Agreement valued at $138,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~March 18, 2022~~.

	●	~~25,000~~ ~~restricted shares of common stock as consideration for an Independent Contractor Agreement valued at $69,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~March 18, 2022~~.

	●	~~800,000restricted shares of common stock as consideration for a Membership Interest Purchase Agreement valued at $1,704,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~April 7, 2022~~.

	●	~~50,000~~ ~~restricted shares of common stock as consideration for a Consulting Agreement valued at $107,000. The fair value was determined based on the market price of the Company’s common stock on the date of grant. The shares were issued on~~ ~~May 2, 2022~~.

	●	~~225,000restricted shares of common stock~~ issued for NHL Exchangeable Shares under the terms and conditions of a Share Exchange Agreement which closed on June 24, 2021. The fair value was determined based on the market price of the Company’s common stock on the date of closing. The shares were issued on ~~May 11,~~October 26, 2022.

	●	~~623,929~~2,916,667shares of common stock were issued as ~~consideration~~provided for ~~payment~~in an exchange offer and amendment (the “Hudson Bay Exchange Offer and Amendment”) with Hudson Bay, dated November 14, 2022. Pursuant to the terms of the Hudson Bay Exchange Offer and Amendment, the Company exchanged one share of the Company’s common stock for each share of common stock underlying the warrant to purchase common stock, dated as of December 14, 2021, issued by the Company to Hudson Bay. The shares were issued on November 15, 2022.

	●	1,757,319 shares of common stock were issued as provided for in an exchange offer and amendment (the “CVI Exchange Offer and Amendment”) with CVI. Pursuant to the terms of the CVI Exchange Offer and Amendment, the Company exchanged one share of the Company’s common stock for each share of common stock underlying the warrant to purchase common stock, dated as of December 14, 2021, issued by the Company to CVI. The shares were issued on November 15, 2022.

	●	39,165,890 shares of common stock were issued to a debt holder upon conversion of outstanding debt in the aggregate ~~principal~~ amount of $~~1,244,444~~3,825,307 in principal and ~~an aggregate accrued interest amount of $3,405~~ ~~on the $16.66m+ convertible notes.~~interest. The shares were issued on various dates during the ~~three months~~fiscal quarter ended ~~May 31,~~February 28, 2023.

	●	45,036,411 shares of common stock were issued to a debt holder upon conversion of outstanding debt in the aggregate amount of $4,503,640 in principal and interest. The shares were issued on various dates during the fiscal quarter ended February 28, 2023.

	●	8,907,097 shares of common stock were issued to a debt holder upon conversion of outstanding debt in the aggregate amount of $757,103 in principal and interest. The shares were issued on various dates during the fiscal quarter ended February 28, 2023.

	●	650,000 shares of common stock were issued on January 5, 2023 to various warrant holders upon exercise of their 3-year warrants. The warrants were granted on October 18, 2022, under the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022. The net proceeds were $65,000.

	●	1,159,348 shares of common stock were issued on January 5, 2023 as provided for in the CVI Exchange Offer and Amendment. Pursuant to the terms of the CVI Exchange Offer and Amendment, the Company exchanged one share of the Company’s common stock for each share of common stock underlying the warrant to purchase common stock, dated as of December 14, 2021, issued by the Company to CVI.

	●	330,000 shares of common stock were issued on January 12, 2023 to various warrant holders upon exercise of their 5-year warrants. The warrants were granted on October 18, 2022, under the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022. The net proceeds were $33,000.

	●	330,000 shares of common stock were issued on January 12, 2023 to various warrant holders upon exercise their 3-year warrants. The warrants were granted on October 18, 2022, under the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022. The net proceeds were $33,000.

	●	3,202,019 restricted shares of common stock were issued for NHL Exchangeable Shares as provided for in the Share Exchange Agreement, which closed on June 24, 2021, in which the Company acquired Acenzia. The fair value was determined based on the market price of the Company’s common stock on the date of closing. The shares were issued on January 25, 2023.

	●	955,000 restricted shares of the Company’s common stock were issued as provided for in the Securities Purchase Agreement, dated February 23, 2023, with Mast Hill Fund, L.P. The shares were issued on February 24, 2023.

Outstanding				Exercisable
Number of		Exercise		Number of		Exercise
Options		Price		Options		Price
	227,155	$	1.33		227,155	$	1.33
	992,000		1.60		992,000		1.60
	48,000		1.87		48,000		1.87
	775,000		3.00		775,000		3.00
	72,600		3.80		72,600		3.80
	10,000		5.00		10,000		5.00
	39,480		1.90		39,480		1.90
	2,164,235				2,164,235

	~~(a)~~	~~CAD$2,000,000~~ ~~(approximately $1,592,200~~) is to be issued or allotted to Mr. Mullins only after patent-pending status, in the U.S. or internationally, is designated for all Mullins IP Assets (the “Mullins IP Assets CAD$2m Shares”), as either restricted shares of Company common stock or NHL Exchangeable Shares, as determined by Mr. Mullins. Once issued or allotted, the Mullins IP Assets CAD $2m Shares will be held in escrow pending registration ~~and approval for all Mullins IP Assets, and~~

	~~(b)~~	~~CAD$500,000~~ ~~(approximately $398,050) is to be issued in the form of~~ ~~118,821~~ ~~restricted shares of Company common stock, free and clear of all liens, pledges, encumbrances, charges, or known claims of any kind, nature, or description, upon closing of the Mullins APA~~

Cash and cash equivalents	$	7,629
Accounts receivable		2,754
Property and equipment		8,813
Goodwill		31,705
Minority interest		(25,401	)
Purchase price	$	25,500

Cash and cash equivalents	$	18,383
Accounts receivable		44,289
Prepaid expenses and other current assets		11,292
Property and equipment		9,475
Goodwill		151,686
Purchase price	$	235,125

Cash and cash equivalents	$	2,186
Goodwill		1,701,814
Purchase price	$	1,704,000

	~~Audit Committee~~	~~Compensation Committee~~	~~Nominating and Corporate Governance Committee~~
~~Michael Pope~~	~~Chair~~	~~Member~~	~~Member~~
~~Sarfaraz Ali~~	~~Member~~	~~Chair~~	~~Member~~
~~Alex Flesias~~	~~Member~~	~~Member~~	~~Chair~~

	●	First ~~Pillar:~~Pillar – Service ~~Networks.~~Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.

	●	Second ~~Pillar: Technology.~~Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.

	●	Third ~~Pillar: Products.~~Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

	~~(a)~~●	For each and every $50 million Company MCV increase sustained for a period of not less than 30 days (the “50M Bonus Event”), Dr. Chalil will receive $250,000, or 0.5% of $50 million, in Company common stock. For the sake of clarity, Dr. Chalil will only be issued compensation based on $50 million MCV increments; there will be no compensation issued for anything above $50 million until the subsequent $50 million MCV milestone is achieved. This bonus will be capped at a Company MCV of $1 billion. The ~~50M Bonus Event stock will be issued as (i) 50% restricted shares within 30 days~~closing of the ~~respective 50M Bonus Event or at a~~SWAG Purchase will occur no later ~~date as requested by Dr. Chalil, and held as an allocation to Dr. Chalil, until the requisition date as provided in writing, by Dr. Chalil,~~than January 10, 2023, with all contemplated extensions being subject to the ~~Company,~~Receiver’s stipulations, conditions, and ~~(ii) 50% registered shares from the Company’s current active incentive plan within 30 days of the respective 50M Bonus Event.~~limitations.

	~~(b)~~●	~~Upon~~The condition for the Company ~~sustaining~~to provide SWAG with a MCV of $2 billion for no less than 30 days (the “2B Bonus Event”), Dr. Chalil will receive $20 million, or 1% of $2 billion, in restricted shares of Company common stock. The 2B Bonus Event stock will be issued within 30 days of the 2B Bonus Event or at a later date as requested by Dr. Chalil, and held as an allocation to Dr. Chalil, until Dr. Chalil provides the Company with written instructions requesting the specific stock issuance date.binding LOI has been deleted.

	~~(c)~~	~~For each additional $1 billion MCV, beyond~~
	●	A total of $92 million will be distributed as follows: (i) $60 million will be distributed to the ~~2B Bonus Event and commencing when~~Receiver for the ~~Company MCV reaches $3 billion sustained for no less than 30 days, Dr. Chalil will receive $10 million, or 1% of $1 billion, in restricted shares~~purchase of the ~~Company’s common stock. Dr. Chalil may choose to have this stock issued within 30 days~~Gems by SWAG, and (ii) a $32 million mark-up will be distributed directly for the benefit of ~~each additional $1 billion MCV event or at a later date as requested by Dr. Chalil, and held as an allocation to Dr. Chalil, until Dr. Chalil provides~~ the ~~Company with written instructions requesting the specific stock issuance date.~~outgoing SWAG Shareholders.

	●	Healthcare and healthcare related services –- gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

	●	Product sales –- revenue is recorded at the point of time of delivery

Exhibit Number		Description of Document

~~2.1~~10.1		~~Membership Interest~~Share Purchase Agreement, dated ~~March 17,~~as of December 23, 2022, by and among Novo Integrated Sciences, Inc., ~~Clinical Consultants International LLC, each~~SwagCheck Inc. and the shareholders of ~~the members of CCI and Dr. Joseph Chalil~~SwagCheck Inc. (incorporated by reference to Exhibit ~~2.1~~10.1 to the Company’s Current Report on Form 8-K filed with the Commission on December 30, 2022).

10.2		Amendment No. 1 to Share Purchase Agreement, dated as of December 30, 2022, by and among Novo Integrated Sciences, Inc., SwagCheck Inc. and the shareholders of SwagCheck Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on January 6, 2023).

10.3		Promissory Note, dated as of February 23, 2023, by and between the Company and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on March ~~23, 2022)~~1, 2023).

~~10.1~~10.4		~~Executive Employment~~Securities Purchase Agreement, dated as of February 23, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on March 1, 2023).

10.5		Promissory Note, dated as of March 21, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on March 27, 2023).

10.6		Securities Purchase Agreement, dated as of March 21, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on March 27, 2023).

10.7		Letter Agreement, dated December 13, 2022, by and among the Company, Terragenx Inc. and Jefferson Street Capital LLC (incorporated by reference to Exhibit 10.49 to the Company’s Annual Report on Form 10-K filed with the Commission on April 3, 2023).

10.8		Securities Purchase Agreement, dated as of April ~~5, 2022~~26, 2023, by and between the registrant and ~~Dr. Joseph Mathew Chalil~~RC Consulting Group LLC in favor of SCP Tourbillion Monaco (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on April ~~7, 2022)~~27, 2023).

10.9		Promissory Note, dated as of April 26, 2023, issued by the registrant to RC Consulting Group LLC in favor of SCP Tourbillion Monaco (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on April 27, 2023).

31.1*		Rule 13a-14(a) Certification of Principal Executive Officer.

31.2*		Rule 13a-14(a) Certification of Principal Financial Officer.

32.1**		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer.

101.INS*		Inline XBRL Instance Document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase

104*		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Outstanding and Exercisable

Number of

Exercise

Warrants